

14-07-2004

REC'D 30 JUL 2004  
WIPO PCT

**Intyg  
Certificate**

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) Sökande            AstraZeneca AB, Södertälje SE  
Applicant (s)

(21) Patentansökningsnummer    0302090-6  
Patent application number

(86) Ingivningsdatum            2003-07-16  
Date of filing

**BEST AVAILABLE COPY**

Stockholm, 2004-04-30

För Patent- och registreringsverket  
For the Patent- and Registration Office

*Hjördis Segerlund*

Hjördis Segerlund

Avgift  
Fee        170:-

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

CHEMICAL COMPOUNDS

The present invention relates to heterocyclic derivatives having pharmaceutical activity, to processes for preparing such derivatives, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives as active therapeutic agents.

Pharmaceutically active piperidine derivatives are disclosed in WO01/87839, EP-A1-1013276, WO00/08013, WO99/38514 and WO99/04794.

Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation and also play a rôle in the maturation of cells of the immune system. Chemokines play an important rôle in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C, or  $\alpha$ ) and Cys-Cys (C-C, or  $\beta$ ) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.

The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).

The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 $\alpha$  and 1 $\beta$  (MIP-1 $\alpha$  and MIP-1 $\beta$ ).

Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.


The CCR5 receptor is expressed on T-lymphocytes, monocytes, macrophages, dendritic cells, microglia and other cell types. These detect and respond to several chemokines, principally "regulated on activation normal T-cell expressed and secreted"

(RANTES), macrophage inflammatory proteins (MIP) MIP-1 $\alpha$  and MIP-1 $\beta$  and monocyte chemoattractant protein-2 (MCP-2).

This results in the recruitment of cells of the immune system to sites of disease. In many diseases it is the cells expressing CCR5 which contribute, directly or indirectly, to tissue damage. Consequently, inhibiting the recruitment of these cells is beneficial in a wide range of diseases.

CCR5 is also a co-receptor for HIV-1 and other viruses, allowing these viruses to enter cells. Blocking the receptor with a CCR5 antagonist or inducing receptor internalisation with a CCR5 agonist protects cells from viral infection.

The present invention provides a compound of formula (I):



wherein:

A is absent or is (CH<sub>2</sub>)<sub>2</sub>;

R<sup>1</sup> is C(O)NR<sup>10</sup>R<sup>11</sup>, C(O)<sub>2</sub>R<sup>12</sup>, NR<sup>13</sup>C(O)R<sup>14</sup>, NR<sup>15</sup>C(O)NR<sup>16</sup>R<sup>17</sup>, NR<sup>18</sup>C(O)<sub>2</sub>R<sup>19</sup>, heterocyclyl (for example piperidine, piperazine, pyrrolidine or azetidine), aryl or heteroaryl;

R<sup>10</sup>, R<sup>13</sup>, R<sup>15</sup>, R<sup>16</sup> and R<sup>18</sup> are hydrogen or C<sub>1-6</sub> alkyl;

R<sup>11</sup>, R<sup>12</sup>, R<sup>14</sup>, R<sup>17</sup> and R<sup>19</sup> are C<sub>1-8</sub> alkyl (optionally substituted by halo, hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, C<sub>3-6</sub> cycloalkyl (optionally substituted by halo), C<sub>5-6</sub> cycloalkenyl, S(C<sub>1-4</sub> alkyl), S(O)(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), heteroaryl, aryl, heteroaryloxy or aryloxy), aryl,

heteroaryl, C<sub>3-7</sub> cycloalkyl (optionally substituted by halo or C<sub>1-4</sub> alkyl), C<sub>4-7</sub> cycloalkyl fused to a phenyl ring, C<sub>5-7</sub> cycloalkenyl, or, heterocyclyl (itself optionally substituted by oxo, C(O)(C<sub>1-6</sub> alkyl), S(O)<sub>k</sub>(C<sub>1-6</sub> alkyl), halo or C<sub>1-4</sub> alkyl); or R<sup>11</sup>, R<sup>12</sup>, R<sup>14</sup> and R<sup>17</sup> can also be hydrogen;

or R<sup>10</sup> and R<sup>11</sup>, and/or R<sup>16</sup> and R<sup>17</sup> may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C<sub>1-6</sub> alkyl, S(O)(C<sub>1-6</sub> alkyl) or C(O)(C<sub>1-6</sub> alkyl);

R<sup>2</sup> is phenyl, heteroaryl or C<sub>3-7</sub> cycloalkyl;

R<sup>3</sup> is H or C<sub>1-4</sub> alkyl;

R<sup>4</sup> is heterocyclyl;

30 n is 1, 2 or 3;

aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, cyano, nitro, hydroxy, OC(O)NR<sup>20</sup>R<sup>21</sup>, NR<sup>22</sup>R<sup>23</sup>, NR<sup>24</sup>C(O)R<sup>25</sup>, NR<sup>26</sup>C(O)NR<sup>27</sup>R<sup>28</sup>, S(O)<sub>2</sub>NR<sup>29</sup>R<sup>30</sup>, NR<sup>31</sup>S(O)<sub>2</sub>R<sup>32</sup>, C(O)NR<sup>33</sup>R<sup>34</sup>, CO<sub>2</sub>R<sup>36</sup>, NR<sup>37</sup>CO<sub>2</sub>R<sup>38</sup>, S(O)<sub>q</sub>R<sup>39</sup>, OS(O)<sub>2</sub>R<sup>49</sup>, C<sub>1-6</sub> alkyl (optionally mono-substituted by S(O)<sub>2</sub>R<sup>50</sup> or C(O)NR<sup>51</sup>R<sup>52</sup>), C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl,

- 5 C<sub>3-10</sub> cycloalkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkoxy(C<sub>1-4</sub>)alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, phenyl, phenyl(C<sub>1-4</sub>)alkyl, phenoxy, phenylthio, phenylS(O), phenylS(O)<sub>2</sub>, phenyl(C<sub>1-4</sub>)alkoxy, heteroaryl, heteroaryl(C<sub>1-4</sub>)alkyl, heteroaryloxy or heteroaryl(C<sub>1-4</sub>)alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(C<sub>1-4</sub> alkyl), S(O)(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>NH<sub>2</sub>, S(O)<sub>2</sub>NH(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>N(C<sub>1-4</sub> alkyl)<sub>2</sub>, cyano, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C(O)NH<sub>2</sub>, C(O)NH(C<sub>1-4</sub> alkyl), C(O)N(C<sub>1-4</sub> alkyl)<sub>2</sub>, CO<sub>2</sub>H, CO<sub>2</sub>(C<sub>1-4</sub> alkyl), NHC(O)(C<sub>1-4</sub> alkyl), NHS(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), CF<sub>3</sub> or OCF<sub>3</sub>;
- 10 unless otherwise stated heterocyclyl is optionally substituted by C<sub>1-6</sub> alkyl [optionally substituted by phenyl {which itself optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, cyano, nitro, CF<sub>3</sub>, OCF<sub>3</sub>, (C<sub>1-4</sub> alkyl)C(O)NH, S(O)<sub>2</sub>NH<sub>2</sub>, C<sub>1-4</sub> alkylthio, S(O)(C<sub>1-4</sub> alkyl) or S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl)} or heteroaryl {which itself optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, cyano, nitro, CF<sub>3</sub>, (C<sub>1-4</sub> alkyl)C(O)NH, S(O)<sub>2</sub>NH<sub>2</sub>, C<sub>1-4</sub> alkylthio, S(O)(C<sub>1-4</sub> alkyl) or S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl)}], phenyl {optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, cyano, nitro, CF<sub>3</sub>, OCF<sub>3</sub>, (C<sub>1-4</sub> alkyl)C(O)NH, S(O)<sub>2</sub>NH<sub>2</sub>, C<sub>1-4</sub> alkylthio, S(O)(C<sub>1-4</sub> alkyl) or S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl)}, heteroaryl {optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, cyano, nitro, CF<sub>3</sub>, (C<sub>1-4</sub> alkyl)C(O)NH, S(O)<sub>2</sub>NH<sub>2</sub>, C<sub>1-4</sub> alkylthio, S(O)(C<sub>1-4</sub> alkyl) or S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl)}, S(O)<sub>2</sub>NR<sup>40</sup>R<sup>41</sup>, C(O)R<sup>42</sup>, C(O)<sub>2</sub>(C<sub>1-6</sub> alkyl) (such as tert-butoxycarbonyl), C(O)<sub>2</sub>(phenyl(C<sub>1-2</sub> alkyl)) (such as benzyloxycarbonyl), C(O)NHR<sup>43</sup>, S(O)<sub>2</sub>R<sup>44</sup>, NHS(O)<sub>2</sub>NHR<sup>45</sup>, NHC(O)R<sup>46</sup>, NHC(O)NHR<sup>47</sup> or NHS(O)<sub>2</sub>R<sup>48</sup>, provided none of these last four substituents is linked to a

25 ring nitrogen;

k, l and q are, independently, 0, 1 or 2;

R<sup>20</sup>, R<sup>22</sup>, R<sup>24</sup>, R<sup>26</sup>, R<sup>27</sup>, R<sup>29</sup>, R<sup>31</sup>, R<sup>33</sup>, R<sup>37</sup>, R<sup>40</sup> and R<sup>51</sup> are, independently, hydrogen or C<sub>1-6</sub> alkyl;

R<sup>21</sup>, R<sup>23</sup>, R<sup>25</sup>, R<sup>28</sup>, R<sup>30</sup>, R<sup>32</sup>, R<sup>34</sup>, R<sup>36</sup>, R<sup>38</sup>, R<sup>39</sup>, R<sup>41</sup>, R<sup>42</sup>, R<sup>43</sup>, R<sup>44</sup>, R<sup>45</sup>, R<sup>46</sup>, R<sup>47</sup>, R<sup>48</sup>, R<sup>49</sup>, R<sup>50</sup>

30 and R<sup>52</sup> are, independently, C<sub>1-6</sub> alkyl (optionally substituted by halo, hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, C<sub>3-6</sub> cycloalkyl, C<sub>5-6</sub> cycloalkenyl, S(C<sub>1-4</sub> alkyl), S(O)(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), heteroaryl, phenyl, heteroaryloxy or phenoxy), C<sub>3-7</sub> cycloalkyl, phenyl or heteroaryl; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally

substituted with halo, hydroxy, nitro, S(C<sub>1-4</sub> alkyl), S(O)(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>NH<sub>2</sub>, S(O)<sub>2</sub>NH(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>N(C<sub>1-4</sub> alkyl)<sub>2</sub>, cyano, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C(O)NH<sub>2</sub>, C(O)NH(C<sub>1-4</sub> alkyl), C(O)N(C<sub>1-4</sub> alkyl)<sub>2</sub>, CO<sub>2</sub>H, CO<sub>2</sub>(C<sub>1-4</sub> alkyl), NHC(O)(C<sub>1-4</sub> alkyl), NHS(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), C(O)(C<sub>1-4</sub> alkyl), CF<sub>3</sub> or OCF<sub>3</sub>;

5 R<sup>21</sup>, R<sup>23</sup>, R<sup>25</sup>, R<sup>28</sup>, R<sup>30</sup>, R<sup>34</sup>, R<sup>35</sup>, R<sup>36</sup>, R<sup>41</sup>, R<sup>42</sup>, R<sup>43</sup>, R<sup>45</sup>, R<sup>46</sup>, R<sup>47</sup> and R<sup>52</sup> may additionally be hydrogen;

or a pharmaceutically acceptable salt thereof or a solvate thereof.

Certain compounds of the present invention can exist in different isomeric forms (such as enantiomers, diastereomers, geometric isomers or tautomers). The present invention covers all such isomers and mixtures thereof in all proportions.

10 Suitable salts include acid addition salts such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate.

The compounds of the invention may exist as solvates (such as hydrates) and the present invention covers all such solvates.

15 Alkyl groups and moieties are straight or branched chain and, for example, comprise one to six (such as one to four) carbon atoms. Alkyl is, for example, methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, sec-butyl or tert-butyl. Methyl is sometimes abbreviated to Me hereinbelow.

20 Haloalkyl includes CF<sub>3</sub>, and haloalkoxy includes CF<sub>3</sub>.

Fluoroalkyl includes, for example, one to six, such as one to three, fluorine atoms, and comprises, for example, a CF<sub>3</sub> group. Fluoroalkyl is, for example, CF<sub>3</sub> or CH<sub>2</sub>CF<sub>3</sub>.

Cycloalkyl is, for example, cyclopropyl, cyclopentyl or cyclohexyl (such as cyclohexyl). Cycloalkenyl includes cyclopentenyl.

25 Heterocyclyl is non-aromatic and is linked by a ring-carbon or ring-heteroatom (such as a ring-nitrogen), and is, for example, a 3-7-membered ring comprising at least one nitrogen, oxygen or sulphur atom. In one embodiment of the invention heterocyclyl has an oxygen atom; a sulphur atom; or, a nitrogen atom and, optionally, an oxygen atom or a sulphur atom. Heterocyclyl is, for example, piperidine, piperazine, pyrrolidine, azetidine, tetrahydrofuran, morpholine or thiomorpholine.

30 Aryl includes phenyl and naphthyl. In one aspect of the invention aryl is phenyl.

Heteroaryl is, for example, an aromatic 5 or 6 membered ring, optionally fused to one or more other rings, comprising at least one heteroatom selected from the group comprising

nitrogen, oxygen and sulphur; or an N-oxide thereof, or an S-oxide or S-dioxide thereof. Heteroaryl is, for example, furyl, thienyl (also known as thiophenyl), pyrrolyl, thiazolyl, isothiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, [1,2,4]-triazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzo[b]furyl (also known as benzfuryl), benz[b]thienyl (also known as benzthienyl or benzthiophenyl), indazolyl, benzimidazolyl, benztriazolyl, 5 benzoxazolyl, benzthiazolyl, 1,2,3-benzothiadiazolyl, an imidazopyridinyl (such as imidazo[1,2a]pyridinyl), thieno[3,2-b]pyridin-6-yl, 1,2,3-benzoxadiazolyl (also known as benzo[1,2,3]thiadiazolyl), 2,1,3-benzothiadiazolyl, benzofurazan (also known as 2,1,3-benzoxadiazolyl), quinoxalinyl, a pyrazolopyridine (for example 1H-pyrazolo[3,4-b]pyridinyl), quinolinyl, isoquinolinyl, a naphthyridinyl (for example [1,6]naphthyridinyl or [1,8]naphthyridinyl), a benzothiazinyl or dibenzothiophenyl (also known as dibenzothienyl); or an N-oxide thereof, or an S-oxide or S-dioxide thereof.

Aryloxy includes phenoxy.

Heteroaryloxy includes pyridinyloxy and pyrimidinyloxy.

15 Phenyl(C<sub>1-4</sub> alkyl)alkyl is, for example, benzyl, 1-(phenyl)eth-1-yl or 1-(phenyl)eth-2-yl.

Heteroaryl(C<sub>1-4</sub> alkyl)alkyl is, for example, pyridinylmethyl, pyrimidinylmethyl or 1-(pyridinyl)eth-2-yl.

Phenyl(C<sub>1-4</sub> alkoxy) is, for example, benzyloxy or phenylCH(CH<sub>3</sub>)O.

20 Heteroaryl(C<sub>1-4</sub> alkoxy) is, for example, pyridinylCH<sub>2</sub>O, pyrimidinylCH<sub>2</sub>O or pyridinylCH(CH<sub>3</sub>)O.

Heteroaryl rings can carry various substituents including sulphonyl groups. A sulphonyl group on a heteroaryl ring can be a good leaving group (susceptible to nucleophilic displacement) and examples of such situation are: 2-methanesulphonyl-pyridine and 2- or 4-methanesulphonyl-pyrimidine. The present invention covers compounds including a 25 heteroaryl ring carrying a sulphonyl group which are sufficiently stable (non-reactive) to be isolated using the experimental procedures described.

In one particular aspect the present invention provides a compound of formula (I) wherein: R<sup>4</sup> is heterocyclyl optionally substituted by C<sub>1-6</sub> alkyl, C(O)H, C(O)(C<sub>1-6</sub> alkyl) or S(O)<sub>2</sub>(C<sub>1-6</sub> alkyl); and a carbon atom of a heterocyclyl ring may also be substituted by halo (for example fluoro) or hydroxy.

30 In another aspect the present invention provides a compound of formula (I) wherein, unless specified otherwise aryl, phenyl and heteroaryl moieties are independently optionally

substituted by one or more of halo, hydroxy, nitro, S(C<sub>1-4</sub> alkyl), S(O)(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>NH<sub>2</sub>, S(O)<sub>2</sub>NH(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>N(C<sub>1-4</sub> alkyl)<sub>2</sub>, cyano, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C(O)NH<sub>2</sub>, C(O)NH(C<sub>1-4</sub> alkyl), CO<sub>2</sub>H, CO<sub>2</sub>(C<sub>1-4</sub> alkyl), NHC(O)(C<sub>1-4</sub> alkyl), NHS(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F, CH<sub>2</sub>CF<sub>3</sub> or OCF<sub>3</sub>.

5 In a further aspect of the invention heteroaryl is pyrrolyl, thienyl, imidazolyl, thiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl or quinolinyl.

In another aspect of the invention R<sup>10</sup>, R<sup>13</sup>, R<sup>15</sup>, R<sup>16</sup> and R<sup>18</sup> are hydrogen or C<sub>1-4</sub> alkyl (for example methyl). In yet another aspect R<sup>10</sup>, R<sup>13</sup>, R<sup>15</sup>, R<sup>16</sup> and R<sup>18</sup> are hydrogen.

10 In a further aspect of the invention R<sup>11</sup>, R<sup>12</sup>, R<sup>14</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> are C<sub>1-8</sub> alkyl (optionally substituted by halo, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, C<sub>3-6</sub> cycloalkyl (optionally substituted by halo), C<sub>5-6</sub> cycloalkenyl, S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), heteroaryl, phenyl, heteroaryloxy or aryloxy (for example phenoxy)), phenyl, heteroaryl, C<sub>3-7</sub> cycloalkyl (optionally substituted by halo or C<sub>1-4</sub> alkyl), C<sub>4-7</sub> cycloalkyl fused to a phenyl ring, C<sub>5-7</sub> cycloalkenyl, or, heterocyclyl (itself optionally substituted by oxo, C(O)(C<sub>1-6</sub> alkyl), S(O)<sub>k</sub>(C<sub>1-4</sub> alkyl), halo or C<sub>1-4</sub> alkyl); k is 0, 1 or 2; or R<sup>10</sup> and R<sup>11</sup>, and/or R<sup>16</sup> and R<sup>17</sup> may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C<sub>1-6</sub> alkyl or C(O)(C<sub>1-6</sub> alkyl)).

15 In yet another aspect of the invention R<sup>11</sup>, R<sup>12</sup>, R<sup>14</sup>, R<sup>17</sup> and R<sup>19</sup> are C<sub>1-8</sub> alkyl (optionally substituted by halo (such as fluoro)), phenyl (optionally substituted as recited above), C<sub>3-6</sub> cycloalkyl (optionally substituted by halo (such as fluoro)) or C-linked nitrogen containing heterocyclyl (optionally substituted on the ring nitrogen).

20 In another aspect of the invention R<sup>1</sup> is NR<sup>13</sup>C(O)R<sup>14</sup>, wherein R<sup>13</sup> and R<sup>14</sup> are as defined above.

25 In yet another aspect of the invention R<sup>14</sup> is C<sub>1-8</sub> alkyl (optionally substituted by halo (such as fluoro, for example to form CF<sub>3</sub>CH<sub>2</sub>)), phenyl (optionally substituted as recited above), C<sub>3-6</sub> cycloalkyl (optionally substituted by halo (such as fluoro, for example to form 1,1-difluorocyclohex-4-yl)) or C-linked nitrogen containing heterocyclyl (such as pyran or piperidine, optionally substituted on the ring nitrogen).

30 In another aspect the present invention provides a compound of the invention wherein R<sup>14</sup> is C<sub>1-8</sub> alkyl (optionally substituted by halo (such as fluoro, for example to form CF<sub>3</sub>CH<sub>2</sub>)), phenyl (optionally substituted by halo) or C<sub>3-6</sub> cycloalkyl (optionally substituted by halo (such as fluoro, for example to form 1,1-difluorocyclohex-4-yl)).

In a further aspect of the invention heterocycll is optionally substituted (such as singly substituted for example on a ring nitrogen atom when present) by C<sub>1-6</sub> alkyl [optionally substituted by phenyl {which itself optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, cyano, nitro, CF<sub>3</sub>, OCF<sub>3</sub>, (C<sub>1-4</sub> alkyl)C(O)NH, S(O)<sub>2</sub>NH<sub>2</sub>, C<sub>1-4</sub> alkylthio or S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl)}]

5 or heteroaryl {which itself optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, cyano, nitro, CF<sub>3</sub>, (C<sub>1-4</sub> alkyl)C(O)NH, S(O)<sub>2</sub>NH<sub>2</sub>, C<sub>1-4</sub> alkylthio or S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl)}], phenyl {optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, cyano, nitro, CF<sub>3</sub>, OCF<sub>3</sub>, (C<sub>1-4</sub> alkyl)C(O)NH, S(O)<sub>2</sub>NH<sub>2</sub>, C<sub>1-4</sub> alkylthio or S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl)}, heteroaryl {optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, cyano, nitro, CF<sub>3</sub>, (C<sub>1-4</sub> alkyl)C(O)NH, S(O)<sub>2</sub>NH<sub>2</sub>, C<sub>1-4</sub> alkylthio or 10 S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl)}, S(O)<sub>2</sub>NR<sup>40</sup>R<sup>41</sup>, C(O)R<sup>42</sup>, C(O)NHR<sup>43</sup> or S(O)<sub>2</sub>R<sup>44</sup>; wherein R<sup>40</sup>, R<sup>41</sup>, R<sup>42</sup>, R<sup>43</sup> and R<sup>44</sup> are, independently, hydrogen or C<sub>1-6</sub> alkyl.

In yet another aspect of the invention R<sup>1</sup> is optionally substituted aryl (such as optionally substituted phenyl) or optionally substituted heteroaryl, wherein the optional substituents are as recited above.

15 In a further aspect of the invention R<sup>1</sup> is optionally substituted heterocycll, such as optionally substituted: piperidin-1-yl, piperidin-4-yl, piperazin-1-yl, pyrrolidin-1-yl, pyrrolidin-3-yl, azetidin-1-yl or azetidin-3-yl.

In a still further aspect of the invention the heterocycll of R<sup>1</sup> is mono-substituted by C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, phenyl {optionally substituted by halo (for example fluoro), C<sub>1-4</sub>

20 alkyl (for example methyl), C<sub>1-4</sub> alkoxy (for example methoxy), CF<sub>3</sub> or OCF<sub>3</sub>}, S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl) (for example S(O)<sub>2</sub>CH<sub>3</sub>, S(O)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> or S(O)<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>}, S(O)<sub>2</sub>(C<sub>1-4</sub> fluoroalkyl) (for example S(O)<sub>2</sub>CF<sub>3</sub> or S(O)<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>}, S(O)<sub>2</sub>phenyl {optionally substituted (such as mono- 25 substituted) by halo (for example chloro), cyano, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl) (for example S(O)<sub>2</sub>CH<sub>3</sub> or S(O)<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>) or S(O)<sub>2</sub>(C<sub>1-4</sub> fluoroalkyl) (for example S(O)<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>}), benzyl {optionally substituted by halo (for example chloro or fluoro), C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy (for example methoxy), CF<sub>3</sub> or OCF<sub>3</sub>}, C(O)H, C(O)(C<sub>1-4</sub>

alkyl), benzoyl {optionally substituted by halo (for example chloro or fluoro), C<sub>1-4</sub> alkyl (for example methyl), C<sub>1-4</sub> alkoxy, CF<sub>3</sub> or OCF<sub>3</sub>}, C(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), C(O)NH<sub>2</sub>, C(O)NH(C<sub>1-4</sub> alkyl) or C(O)NHphenyl {optionally substituted by halo (for example fluoro), C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, CF<sub>3</sub> or OCF<sub>3</sub>}. Said heterocycll can also be mono-substituted by S(O)<sub>2</sub>N(C<sub>1-4</sub> 30 alkyl)<sub>2</sub>. In a still further aspect when said heterocycll is a 4-substituted piperidin-1-yl, a 1-substituted piperidin-4-yl, a 4-substituted piperazin-1-yl, a 3-substituted pyrrolidin-1-yl, a 1-substituted pyrrolidin-3-yl, a 3-substituted azetidin-1-yl or a 1-substituted azetidin-3-yl (for

example where said substituent is as recited earlier in this paragraph). In another aspect said heterocyclyl is a 1-substituted piperidin-4-yl or a 4-substituted piperazin-1-yl, wherein the substituent is S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>(C<sub>1-4</sub> haloalkyl), S(O)<sub>2</sub>(phenyl), S(O)<sub>2</sub>N(C<sub>1-4</sub> alkyl)<sub>2</sub> or phenyl.

5       In yet another aspect of the invention R<sup>2</sup> is phenyl or heteroaryl, either of which is optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, S(O)<sub>p</sub>(C<sub>1-4</sub> alkyl), nitro, cyano or CF<sub>3</sub>; wherein p is 0, 1 or 2, for example 0 or 2. When R<sup>2</sup> is heteroaryl it is, for example an optionally substituted thiophenyl.

10      In a still further aspect R<sup>2</sup> is optionally substituted (for example unsubstituted or substituted in the 2-, 3-, or 3- and 5- positions) phenyl (such as optionally substituted by halo (such as chloro or fluoro), cyano, methyl, ethyl, methoxy, ethoxy or CF<sub>3</sub>), or optionally substituted (for example unsubstituted or mono-substituted) heteroaryl (such as optionally substituted by halo (such as chloro or fluoro), cyano, methyl, ethyl, methoxy, ethoxy or CF<sub>3</sub>).


15      In another aspect the invention provides a compound of the invention wherein R<sup>2</sup> is optionally substituted (for example unsubstituted or substituted in the 2-, 3-, or 3- and 5- positions) phenyl (such as optionally substituted by halo (for example chloro or fluoro)). In yet another aspect the invention provides a compound of the invention wherein R<sup>2</sup> is phenyl, 3-fluorophenyl, 3-chlorophenyl, 3-trifluoromethylphenyl, 3-chloro-5-fluorophenyl or 3,5-difluorophenyl. In a further aspect the invention provides a compound of the invention  
20     wherein R<sup>2</sup> is phenyl, 3-fluorophenyl, 3-chlorophenyl or 3,5-difluorophenyl.

In yet another aspect of the invention R<sup>3</sup> is hydrogen or methyl. In a further aspect of the invention when R<sup>3</sup> is C<sub>1-4</sub> alkyl (such as methyl) and the carbon to which R<sup>3</sup> is attached has the R absolute configuration. In yet another aspect of the invention R<sup>3</sup> is hydrogen.

25      In a further aspect the present invention provides a compound of the invention wherein n is 2.

In a still further aspect the invention provides a compound of the invention wherein A is absent.


In a further aspect the present invention provides a compound of formula (Ia):



wherein Y is CH or N; R<sup>1a</sup> is mono-substituted by C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, phenyl {optionally substituted by halo (for example fluoro), C<sub>1-4</sub> alkyl (for example methyl), C<sub>1-4</sub> alkoxy (for example methoxy), CF<sub>3</sub> or OCF<sub>3</sub>}, S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl) (for example S(O)<sub>2</sub>CH<sub>3</sub>,

- 5 S(O)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> or S(O)<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, S(O)<sub>2</sub>(C<sub>1-4</sub> fluoroalkyl) (for example S(O)<sub>2</sub>CF<sub>3</sub> or S(O)<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>), S(O)<sub>2</sub>phenyl {optionally substituted (such as mono-substituted) by halo (for example chloro), cyano, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl) (for example S(O)<sub>2</sub>CH<sub>3</sub> or S(O)<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>) or S(O)<sub>2</sub>(C<sub>1-4</sub> fluoroalkyl) (for example S(O)<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>)}, benzyl {optionally substituted by halo (for example chloro or fluoro), C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy
- 10 (for example methoxy), CF<sub>3</sub> or OCF<sub>3</sub>}, C(O)H, C(O)(C<sub>1-4</sub> alkyl), benzoyl {optionally substituted by halo (for example chloro or fluoro), C<sub>1-4</sub> alkyl (for example methyl), C<sub>1-4</sub> alkoxy, CF<sub>3</sub> or OCF<sub>3</sub>}, C(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), C(O)NH<sub>2</sub>, C(O)NH(C<sub>1-4</sub> alkyl), C(O)NPhenyl {optionally substituted by halo (for example fluoro), C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, CF<sub>3</sub> or OCF<sub>3</sub>} or S(O)<sub>2</sub>N(C<sub>1-4</sub> alkyl)<sub>2</sub>; R<sup>2a</sup> and R<sup>2b</sup> are, independently, hydrogen or halo (for example fluoro);
- 15 and R<sup>4</sup> is heterocyclyl optionally substituted by C<sub>1-6</sub> alkyl, C(O)H, C(O)(C<sub>1-6</sub> alkyl) or S(O)<sub>2</sub>(C<sub>1-6</sub> alkyl); and a carbon atom of a heterocyclyl ring may also be substituted by halo (for example fluoro) or hydroxy.


In a further aspect the present invention provides a compound of formula (Ib):



- 20 wherein R<sup>2a</sup>, R<sup>2b</sup>, R<sup>14</sup> and R<sup>4</sup> are as defined above.

In a still further aspect the present invention provides a compound of formula (Ic):

10



wherein R<sup>1b</sup> is halo, hydroxy, nitro, S(C<sub>1-4</sub> alkyl), S(O)(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>NH<sub>2</sub>, S(O)<sub>2</sub>NH(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>N(C<sub>1-4</sub> alkyl)<sub>2</sub>, cyano, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C(O)NH<sub>2</sub>, C(O)NH(C<sub>1-4</sub> alkyl), CO<sub>2</sub>H, CO<sub>2</sub>(C<sub>1-4</sub> alkyl), NHC(O)(C<sub>1-4</sub> alkyl), NHS(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F, CH<sub>2</sub>CF<sub>3</sub> or OCF<sub>3</sub>; and R<sup>2a</sup>, R<sup>2b</sup> and R<sup>4</sup> are as defined above.


In yet another aspect of the invention there is provided a compound of formula (Ia), (Ib) or (Ic) wherein R<sup>2a</sup> and R<sup>2b</sup> are, independently, hydrogen, halo (such as chloro or fluoro) or CF<sub>3</sub>.

The compounds listed in Tables I, II and III illustrate the invention.

10

Table I

Table I comprises compounds of formula (Ia)




Compound No	R <sup>1a</sup>	R <sup>2a</sup>	R <sup>2b</sup>	R <sup>4</sup>	Y	MS (MH <sup>+</sup> )
1	methanesulphonyl	F	F	Piperidin-1-yl	CH	

15

Table II

Table II comprises compounds of formula (Ib)


11



Compound No	R <sup>14</sup>	R <sup>2a</sup>	R <sup>2b</sup>	R <sup>4</sup>	MS (MH <sup>+</sup> )
1	3,3,3-Trifluoropropyl	F	F	Piperidin-1-yl	

Table III

Table III comprises compounds of formula (Ic)




5

Compound No	R <sup>1b</sup>	R <sup>2a</sup>	R <sup>2b</sup>	R <sup>4</sup>	Adduct	MS (MH <sup>+</sup> )
1	S(O) <sub>2</sub> CH <sub>3</sub>	F	F	Piperidin-1-yl	HCl	569

In yet another aspect the invention provides each individual compound listed in the tables above.


The compounds of formula (I), (Ia), (Ib) and (Ic) are all compounds of the invention can be prepared as shown below. In the processes and Schemes presented it will be apparent to a person skilled in the art that if a reactive group (such as an NH group) is present then, for certain reactions, that group will need to be protected and subsequently deprotected. Also, it may be necessary to protect two reactive groups and then selectively deprotect. The use of protecting groups is described in 'Protective Groups in Organic Synthesis', 2nd edition, T.W. Greene & P.G.M. Wutz, Wiley-Interscience (1991).

A compound of the invention wherein R<sup>1</sup> is an N-linked optionally substituted heterocycle can be prepared by reacting a compound of formula (II):




wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, m, n, A and X are as defined above, with a compound R<sup>1</sup>H (wherein the H is on a heterocycle ring nitrogen atom) wherein R<sup>1</sup> is as defined above, in the presence of a suitable base (for example a tri(C<sub>1-6</sub> alkyl)amine such as triethylamine or Hunig's base), in a suitable solvent (such as a chlorinated solvent, for example dichloromethane) and, for example, at a room temperature (for example 10-30°C), optionally in the presence of sodium iodide.

10 A compound of the invention, wherein R<sup>3</sup> is hydrogen, can be prepared by coupling a compound of formula (III):




wherein R<sup>4</sup>, m, n, A and X are as defined above, with a compound of formula (IV):




15 wherein R<sup>1</sup> and R<sup>2</sup> are as defined above, in the presence of NaBH(OAc)<sub>3</sub> (wherein Ac is C(O)CH<sub>3</sub>) in a suitable solvent (such as a chlorinated solvent, for example dichloromethane) at room temperature (for example 10-30°C).

A compound of the invention, wherein R<sup>3</sup> is hydrogen, can be prepared by coupling a compound of formula (III):



wherein R<sup>4</sup>, m, n, A and X are as defined above, with a compound of formula (V):



wherein R<sup>1</sup> and R<sup>2</sup> are as defined above and L is a leaving group such as halogen, tosylate, mesylate or triflate, in the presence of a base, such as potassium carbonate, in a suitable solvent (such as dioxane, acetonitrile or isopropanol) at temperatures from 60°C up to the boiling point of the solvent.

5        Alternatively, compounds of the invention can be prepared according to Schemes 1-7 (below). Note that in Scheme 6 the use of a homochiral diol will result in the synthesis of homochiral product.

Alternatively, compounds of the invention can be prepared by using or adapting methods described in WO01/87839, EP-A1-1013276, WO00/08013, WO99/38514, 10 WO99/04794, WO00/76511, WO00/76512, WO00/76513, WO00/76514, WO00/76972 or US 2002/0094989.

The starting materials for these processes are either commercially available or can be prepared by literature methods, adapting literature methods or by following or adapting Methods herein described.

15      In a still further aspect the invention provides processes for preparing the compounds of formula (I), (Ia), (Ib) and (Ic). Many of the intermediates in the processes are novel and these are provided as further features of the invention.

20      The compounds of the invention have activity as pharmaceuticals, in particular as modulators (such as agonists, partial agonists, inverse agonists or antagonists) of chemokine receptor (such as CCR5) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative or hyperproliferative diseases, or immunologically-mediated diseases (including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS)).

25      The compounds of the present invention are also of value in inhibiting the entry of viruses (such as human immunodeficiency virus (HIV)) into target cells and, therefore, are of value in the prevention of infection by viruses (such as HIV), the treatment of infection by viruses (such as HIV) and the prevention and/or treatment of acquired immune deficiency syndrome (AIDS).

30      According to a further feature of the invention there is provided a compound of the formula (I), (Ia), (Ib) and (Ic), or a pharmaceutically acceptable salt thereof or a solvate thereof, for use in a method of treatment of a warm blooded animal (such as man) by therapy (including prophylaxis).

According to a further feature of the present invention there is provided a method for modulating chemokine receptor activity (such as CCR5 receptor activity) in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof or a solvate thereof.

The present invention also provides the use of a compound of the formula (I), (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt thereof or a solvate thereof, as a medicament, such as a medicament for the treatment of transplant rejection, respiratory disease, psoriasis or rheumatoid arthritis (such as rheumatoid arthritis). [Respiratory disease is, for example, COPD, asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)} or rhinitis {acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis}; and is particularly asthma or rhinitis].

In another aspect the present invention provides the use of a compound of the formula (I), (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (such as CCR5 receptor activity (such as rheumatoid arthritis)) in a warm blooded animal, such as man).

The invention also provides a compound of the formula (I), (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt thereof or a solvate thereof, for use as a medicament, such as a medicament for the treatment of rheumatoid arthritis.

In another aspect the present invention provides the use of a compound of the formula (I), (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (such as CCR5 receptor activity (such as rheumatoid arthritis)) in a warm blooded animal, such as man).

The invention further provides the use of a compound of formula (I), (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of the following disease states:

(1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)}; bronchitis {such as eosinophilic bronchitis}; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polypsis; fibroid lung or idiopathic interstitial pneumonia;

(2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behcet's disease, Sjogren's syndrome or systemic sclerosis;

(3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, Alopecia areata or vernal conjunctivitis;

(4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);

(5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or

(6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridental disease, Sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle;

in a warm blooded animal, such as man.

The present invention further provides a method of treating a chemokine mediated disease state (such as a CCR5 mediated disease state) in a warm blooded animal, such as man,

which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I), (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt thereof or solvate thereof.

In order to use a compound of the invention, or a pharmaceutically acceptable salt thereof or solvate thereof, for the therapeutic treatment of a warm blooded animal, such as man, in particular modulating chemokine receptor (for example CCR5 receptor) activity, said ingredient is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I), (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt thereof or a solvate thereof (active ingredient), and a pharmaceutically acceptable adjuvant, diluent or carrier. In a further aspect the present invention provides a process for the preparation of said composition which comprises mixing active ingredient with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will, for example, comprise from 0.05 to 99 %w (per cent by weight), such as from 0.05 to 80 %w, for example from 0.10 to 70 %w, such as from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by topical (such as to the lung and/or airways or to the skin), oral, rectal or parenteral administration. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, aerosols, dry powder formulations, tablets, capsules, syrups, powders, granules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, drops and sterile injectable aqueous or oily solutions or suspensions.

A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 0.1mg and 1g of active ingredient.

In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection.

Each patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of  $0.01\text{mgkg}^{-1}$  to  $100\text{mgkg}^{-1}$  of the compound, for example in the range of  $0.1\text{mgkg}^{-1}$  to

20mgkg<sup>-1</sup> of this invention, the composition being administered 1 to 4 times per day. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is

5 approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.

The following illustrate representative pharmaceutical dosage forms containing the compound of formula (I), (Ia), (Ib) or (Ic), or a pharmaceutically acceptable salt thereof or a solvent thereof (hereafter Compound X), for therapeutic or prophylactic use in humans:

10 (a)

<u>Tablet I</u>	<u>mg/tablet</u>
Compound X	100
Lactose Ph.Eur.	179
Croscarmellose sodium	12.0
Polyvinylpyrrolidone	6
Magnesium stearate	3.0

(b)

<u>Tablet II</u>	<u>mg/tablet</u>
Compound X	50
Lactose Ph.Eur.	229
Croscarmellose sodium	12.0
Polyvinylpyrrolidone	6
Magnesium stearate	3.0

(c)

<u>Tablet III</u>	<u>mg/tablet</u>
Compound X	1.0
Lactose Ph.Eur.	92
Croscarmellose sodium	4.0
Polyvinylpyrrolidone	2.0
Magnesium stearate	1.0

(d)

<u>Capsule</u>	<u>mg/capsule</u>
Compound X	10
Lactose Ph.Eur.	389
Croscarmellose sodium	100
Magnesium stearate	1.0

5 (e)

<u>Injection I</u>	<u>(50 mg/ml)</u>
Compound X	5.0% w/v
Isotonic aqueous solution	to 100%

Buffers, pharmaceutically-acceptable cosolvents such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl  $\beta$ -cyclodextrin may be used to aid formulation.

10

The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

15

The invention further relates to combination therapies or compositions wherein a compound of formula (I), or a pharmaceutically acceptable salt, solvate or a solvate of a salt thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate or a solvate of a salt thereof, is administered concurrently (possibly in the same composition) or sequentially with an agent for the treatment of any one of the above disease states.

In particular, for the treatment of the inflammatory diseases rheumatoid arthritis, psoriasis, inflammatory bowel disease, COPD, asthma and allergic rhinitis a compound of the invention can be combined with a TNF- $\alpha$  inhibitor (such as an anti-TNF monoclonal antibody (such as Remicade, CDP-870 and D.sub2.E.sub7.), or a TNF receptor

5 immunoglobulin molecule (such as Enbrel.reg.)), a non-selective COX-1 / COX-2 inhibitor (such as piroxicam or diclofenac; a propionic acid such as naproxen, flubiprofen, fenoprofen, ketoprofen or ibuprofen; a fenamate such as mefenamic acid, indomethacin, sulindac or apazone; a pyrazolone such as phenylbutazone; or a salicylate such as aspirin), a COX-2 inhibitor (such as meloxicam, celecoxib, rofecoxib, valdecoxib or etoricoxib) low dose  
10 methotrexate, lefunomide; ciclesonide; hydroxychloroquine, d-penicillamine or auranofin, or parenteral or oral gold.

The present invention still further relates to the combination of a compound of the invention together with:

- a leukotriene biosynthesis inhibitor, a 5-lipoxygenase (5-LO) inhibitor or a 5-lipoxygenase activating protein (FLAP) antagonist, such as zileuton, ABT-761, fenleuton, tepoxalin, Abbott-79175, Abbott-85761, an N-(5-substituted)-thiophene-2-alkylsulfonamide, a 2,6-di-tert-butylphenol hydrazones, a methoxytetrahydropyran such as Zeneca ZD-2138, SB-210661, a pyridinyl-substituted 2-cyanonaphthalene compound such as L-739,010; a 2-cyanoquinoline compound such as L-746,530; an indole or quinoline compound such as MK-591, MK-886 or BAY x 1005;
- a receptor antagonist for a leukotriene LTB<sub>4</sub>, LTC<sub>4</sub>, LTD<sub>4</sub> or LTE<sub>4</sub> selected from the group consisting of a phenothiazin-3-one such as L-651,392; an amidino compound such as CGS-25019c; a benzoxalamine such as ontazolast; a benzenecarboximidamide such as BIIL 284/260; or a compound such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A) or BAY x 7195;
- a PDE4 inhibitor including an inhibitor of the isoform PDE4D;
- an antihistaminic H<sub>1</sub> receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, astemizole, azelastine or chlorpheniramine;
- a gastroprotective H<sub>2</sub> receptor antagonist;
- an  $\alpha_1$ - and  $\alpha_2$ -adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine,

naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride or ethynorepinephrine hydrochloride;

- an anticholinergic agent such as ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine;

5      • a  $\beta_{\text{sub}1}$ - to  $\beta_{\text{sub}4}$ -adrenoceptor agonist such as metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate or pirbuterol, or a methylxanthanine including theophylline and aminophylline; sodium cromoglycate; or a muscarinic receptor (M1, M2, and M3) antagonist;

10     • an insulin-like growth factor type I (IGF-1) mimetic;

      • an inhaled glucocorticoid with reduced systemic side effects, such as prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate or mometasone furoate;

15     • an inhibitor of a matrix metalloprotease (MMP), such as a stromelysin, a collagenase, or a gelatinase or aggrecanase; such as collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11) or MMP-12;

20     • a modulator of chemokine receptor function such as CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX<sub>3</sub>CR1 for the C-X<sub>3</sub>-C family;

25     • an osteoporosis agent such as roloxifene, droloxifene, lasoxifene or fosomax;

      • an immunosuppressant agent such as FK-506, rapamycin, cyclosporine, azathioprine or methotrexate; or,

30     • an existing therapeutic agent for the treatment of osteoarthritis, for example a non-steroidal anti-inflammatory agent (hereinafter NSAID's) such as piroxicam or diclofenac, a propionic acid such as naproxen, flubiprofen, fenoprofen, ketoprofen or ibuprofen, a fenamate such as mefenamic acid, indomethacin, sulindac or apazone, a pyrazolone such as phenylbutazone, a salicylate such as aspirin, a COX-2 inhibitor such as celecoxib, valdecoxib, rofecoxib or etoricoxib, an analgesic or intra-articular therapy such as a corticosteroid or a hyaluronic acid such as hyalgan or synvisc, or a P2X7 receptor antagonist.

The present invention still further relates to the combination of a compound of the invention together with: (i) a tryptase inhibitor; (ii) a platelet activating factor (PAF) antagonist; (iii) an interleukin converting enzyme (ICE) inhibitor; (iv) an IMPDH inhibitor; (v) an adhesion molecule inhibitor including a VLA-4 antagonist; (vi) a cathepsin; (vii) a MAP kinase inhibitor; (viii) a glucose-6 phosphate dehydrogenase inhibitor; (ix) a kinin-B<sub>1</sub> - and B<sub>2</sub>-receptor antagonist; (x) an anti-gout agent, e.g., colchicine; (xi) a xanthine oxidase inhibitor, e.g., allopurinol; (xii) an uricosuric agent, e.g., probenecid, sulfinpyrazone or benzboromarone; (xiii) a growth hormone secretagogue; (xiv) a transforming growth factor (TGF $\beta$ ); (xv) a platelet-derived growth factor (PDGF); (xvi) a fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF); (xvii) a granulocyte macrophage colony stimulating factor (GM-CSF); (xviii) a capsaicin cream; (xix) a Tachykinin NK<sub>1</sub> and NK<sub>3</sub> receptor antagonist selected from the group consisting of NKP-608C; SB-233412 (talnetant); and D-4418; (xx) an elastase inhibitors selected from the group consisting of UT-77 and ZD-0892; (xxi) a TNF $\alpha$  converting enzyme inhibitor (TACE); (xxii) an induced nitric oxide synthase inhibitor (iNOS); or (xxiii) a chemoattractant receptor-homologous molecule expressed on TH2 cells (a CRTH2 antagonist).

The invention will now be illustrated by the following non-limiting Examples in which, unless stated otherwise:

- (i) temperatures are given in degrees Celsius ( $^{\circ}$ C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25 $^{\circ}$ C;
- (ii) organic solutions were dried over anhydrous magnesium sulfate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30 mm Hg) with a bath temperature of up to 60 $^{\circ}$ C;
- (iii) chromatography unless otherwise stated means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates; where a "Bond Elut" column is referred to, this means a column containing 10g or 20g of silica of 40 micron particle size, the silica being contained in a 60ml disposable syringe and supported by a porous disc, obtained from Varian, Harbor City, California, USA under the name "Mega Bond Elut SI". Where an "Isolute<sup>TM</sup> SCX column" is referred to, this means a column containing benzenesulphonic acid (non-endcapped) obtained from International Sorbent Technology Ltd., 1st House, Duffryn Industrial Estate, Ystrad Mynach, Hengoed, Mid Glamorgan, UK. Where "Argonaut<sup>TM</sup> PS-tris-amine scavenger resin" is referred to, this

means a *tri*-(2-aminoethyl)amine polystyrene resin obtained from Argonaut Technologies Inc., 887 Industrial Road, Suite G, San Carlos, California, USA.

(iv) in general, the course of reactions was followed by TLC and reaction times are given for illustration only;

5 (v) yields, when given, are for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required;

(vi) when given,  $^1\text{H}$  NMR data is quoted and is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an

10 internal standard, determined at 300 MHz using perdeuterio DMSO ( $\text{CD}_3\text{SOCD}_3$ ) as the solvent unless otherwise stated; coupling constants ( $J$ ) are given in Hz;

(vii) chemical symbols have their usual meanings; SI units and symbols are used;

(viii) solvent ratios are given in percentage by volume;

(ix) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (APCI) mode using a direct exposure probe; where indicated ionisation was effected by electrospray (ES); where values for  $m/z$  are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion -  $(\text{M}+\text{H})^+$ ;

(x) LCMS characterisation was performed using a pair of Gilson 306 pumps with Gilson 233

20 XL sampler and Waters ZMD4000 mass spectrometer. The LC comprised water symmetry 4.6x50 column C18 with 5 micron particle size. The eluents were: A, water with 0.05% formic acid and B, acetonitrile with 0.05% formic acid. The eluent gradient went from 95% A to 95% B in 6 minutes. Where indicated ionisation was effected by electrospray (ES); where values for  $m/z$  are given, generally only ions which indicate the parent mass are

25 reported, and unless otherwise stated the mass ion quoted is the positive mass ion -  $(\text{M}+\text{H})^+$ ;

(xi) PS-NCO resin is an isocyanate resin and is available from Argonaut; and,

(xii) the following abbreviations are used:

THF                   tetrahydrofuran;

Boc                   tert-butoxycarbonyl

30 DMF               N,N-dimethylformamide

DCM               dichloromethane

DIPEA               N,N-Diisopropylethylamine


R-BINAP           R 2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl

Example 1


This Example illustrates the preparation of (*R*)-1-(3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl)-4-[2-(piperidin-1-ylsulfonyl)ethyl]piperidine hydrochloride (Compound No. 1 of Table III).

A mixture of 1-[(2-piperidin-4-ylethyl)sulfonyl]piperidine hydrochloride (Method B, 400mg, 1.35mmol), (*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl 4-methylbenzenesulfonate (Method C, 600mg, 1.25mmol) and potassium carbonate (500mg, 3.62mmol) in acetonitrile (10mL) was heated to reflux for 6h. The mixture was allowed to

cool then evaporated and the residue partitioned between ethyl acetate and water. The organic phase was evaporated and the residue purified by silica column chromatography. The crude product was treated with a solution of hydrogen chloride in methanol to yield the title compound as a solid (330mg); NMR: 1.4-1.6 (m, 1H), 1.85 (m, 2H), 2.6 (m, 2H), 2.8 (m, 4H), 3.0 (m, 2H), 3.1 (m, 4H), 3.15 (s, 3H), 3.5 (m, 2H), 4.25 (dd, 1H), 7.05 (m, 1H), 7.15 (d, 2H), 7.65 (d, 2H), 7.85 (d, 2H); LC-MS: 569.

**Method A****(S)-3-Phenyl-3-(4-methanesulfonylphenyl)propionaldehyde**

Step 1: Preparation of *E*-(4*S*, 5*R*)-1-(3-[4-methanesulphonylphenyl]acryloyl)-3,4-dimethyl-5-phenyl-imidazolidin-2-one




To a stirred solution of 3-(4-methanesulphonylphenyl)acrylic acid (7.14g, 31.5mmol) in DCM (10mL) was added thionyl chloride (3mL, 34.7mmol) dropwise and the resulting

mixture was stirred at room temperature for 18h. To this solution was added DIPEA (5.04mL, 28.9mmol) dropwise at room temperature. The resulting solution was added to a stirred solution of (*4R, 5S*)-1,5-dimethyl-4-phenyl-imidazolidin-2-one (5.0g, 26.3mmol) in DCM (20mL) and DIPEA (4.58mL, 26.9mmol) and the resulting mixture stirred at room

5 temperature for 4h. The mixture was washed with water and brine, pre-absorbed onto a Bond Elut and eluted with a gradient of isohexane to ethyl acetate giving the title compound as a solid (7.61g, 73%); NMR ( $\text{CDCl}_3$ ): 0.84 (d, 3H), 2.89 (s, 3H), 3.04 (s, 3H), 3.98 (m, 1H), 5.42 (d, 1H), 7.20 (m, 2H), 7.32 (m, 3H), 7.69 (d, 1H), 7.74 (d, 2H), 7.93 (d, 2H), 8.31 (d, 1H); MS: 399.

10

**Step 2: Preparation of (*4S, 5R*)-1-[*(S*)-3-(4-methanesulfonyl-phenyl)-3-phenyl-propionyl]-3,4-dimethyl-5-phenyl-imidazolidin-2-one**



To a mixture of copper (I) iodide (960mg, 5.0mmol) and THF (20mL) was added

15 *N,N,N',N'*-tetramethylethylenediamine (0.83mL, 5.5mmol) and the resulting mixture was stirred at room temperature for 10min. then cooled to -78°C. Phenylmagnesium bromide (5.0mL, 1M in THF, 5.0mmol) was added and the resulting mixture stirred at -78°C for 15min. A solution of di-n-butylboron triflate (3.0mL, 1M in diethyl ether, 3.0mmol) and (*E*)-(4*S, 5R*)-1-(3-[4-methanesulfonylphenyl]acryloyl)-3,4-dimethyl-5-phenyl-imidazolidin-2-one (1.0g, 2.51mmol) in THF (15mL) was added and the resulting mixture was stirred whilst allowing to warm to room temperature for 18h. The reaction mixture was washed with saturated aqueous ammonium chloride, water and brine, dried ( $\text{MgSO}_4$ ) and evaporated. The residue was purified by eluting through a 20g Bond Elut with gradient of isohexane to ethyl acetate giving the sub-titled compound (1.49g, 100%); NMR ( $\text{CDCl}_3$ ): 0.78 (d, 3H), 2.82 (s, 3H), 3.00 (s, 3H), 3.78 (dd, 1H), 3.80 (m, 1H), 3.98 (dd, 1H), 4.72 (m, 1H), 5.19 (d, 1H), 6.99 (m, 2H), 7.22 (m, 8H), 7.48 (d, 2H), 7.79 (d, 2H); MS: 477.

20

25


**Step 3: Preparation of (*S*)-3-phenyl-3-(4-methanesulphonylphenyl)propan-1-ol**

To a solution of (*4S, 5R*)-1-[*(S*)-3-(4-methanesulphonyl-phenyl)-3-phenyl-propionyl]-3,4-dimethyl-5-phenyl-imidazolidin-2-one (846mg, 1.78mmol) in THF (20mL) at 0°C was added lithium aluminium hydride (3.6mL, 1M in THF, 3.6mmol) and the resulting mixture was stirred for 15min. The reaction was quenched by the addition of 2M aqueous sodium hydroxide. The phases were separated and the organic phase pre-absorbed onto a Bond Elut and eluted with a gradient of isohexane to ethyl acetate giving the sub-titled compound as a white solid (285mg, 55%); NMR ( $\text{CDCl}_3$ ): 1.63 (br s, 1H), 2.33 (m, 2H), 3.00 (s, 3H), 3.59 (t, 2H), 4.28 (t, 1H), 7.23 (m, 5H), 7.43 (d, 2H), 7.82 (d, 2H).


10

**Step 4: Preparation of the title compound**

To a solution of (*S*)-3-phenyl-3-(4-methanesulfonylphenyl)propan-1-ol (244mg, 0.84mmol) in DCM (5mL) was added Dess-Martin periodinane (392mg, 0.92mmol) and the resulting mixture was stirred at room temperature for 1.5h. The mixture was washed with 2M aqueous sodium hydroxide (2 x 10mL), dried and evaporated to give the title compound.

**Method B****1-[(2-Piperidin-4-ylethyl)sulfonyl]piperidine hydrochloride**

20 Step 1: Preparation of 2-{1-[(benzyloxy)carbonyl]piperidin-4-yl}ethanesulfonic acid




To 2-pyridin-4-ylethanesulfonic acid (20.0g, 107mmol) in water (200mL) was added concentrated ammonia solution (12mL) and 5% wt/wt rhodium on alumina (5g). The resulting mixture was hydrogenated under 5 atmospheres of hydrogen at 30°C. The mixture was filtered and sodium hydroxide pellets (15g) was added to the filtrate. The resulting mixture was concentrated to 120mL then cooled to 0°C. Benzyl chloroformate (20mL, 140mmol) was added dropwise with stirring. The resulting mixture was stirred for 1h with warming to room temperature. The mixture was washed with diethyl ether then the pH adjusted to 1 with

25

concentrated hydrochloric acid. The mixture was extracted three times with a mixture of DCM and methanol (9:1). The combined extracts were dried and concentrated to give the sub-titled compound as a solid (6.5g); NMR: 0.9 (m, 2H), 1.5 (m, 3H), 1.6 (d, 2H), 2.2 (dd, 2H), 2.7 (m, 2H), 3.95 (d, 2H), 5.05 (s, 2H), 7.3 (m, 5H); LC-MS: 326 (M-H)<sup>-</sup>.


5

**Step 2: Preparation of 2-{1-[(benzyloxy)carbonyl]piperidin-4-yl}ethanesulfonyl chloride**



A mixture of 2-{1-[(benzyloxy)carbonyl]piperidin-4-yl}ethanesulfonic acid (6g) and thionyl chloride (50mL) was heated to reflux for 4h. The mixture was allowed to cool and the liquid was decanted and concentrated. The residue was azeotroped with toluene giving the sub-titled compound as a solid (5.9g); NMR ( $\text{CDCl}_3$ ): 1.2 (m, 2H), 1.7 (m, 3H), 2.0 (m, 2H), 2.8 (dd, 2H), 3.7 (dd, 2H), 4.2 (d, 2H), 5.05 (s, 2H), 7.3 (m, 5H).

**Step 3: Preparation of benzyl 4-[2-(piperidin-1-ylsulfonyl)ethyl]piperidine-1-carboxylate**



15

To a cooled (5°C) solution of 2-{1-[(benzyloxy)carbonyl]piperidin-4-yl}ethanesulfonyl chloride (5.5g) in DCM (100mL) was added piperidine (5.0mL) dropwise. The resulting mixture was stirred for 2h with warming to room temperature. The mixture was washed with 2M hydrochloric acid, dried ( $\text{MgSO}_4$ ) and concentrated. The crude product was purified by silica gel chromatography to give the sub-titled compound (3.4g); NMR ( $\text{CDCl}_3$ ): 1.15 (m, 2H), 1.6 (m, 9H), 1.75 (m, 2H), 2.8 (dd, 2H), 2.9 (dd, 2H), 3.25 (m, 4H), 4.2 (m, 2H), 5.1 (s, 2H), 7.35 (m, 5H); MS: 395.

**Step 4: Preparation of title compound**


To a solution of benzyl 4-[2-(piperidin-1-ylsulfonyl)ethyl]piperidine-1-carboxylate (3.0g, 7.6mmol) in warm ethanol (30mL) was added concentrated hydrochloric acid (0.5mL) and 5% palladium on carbon (300mg). The resulting mixture was stirred under an atmosphere

25

of hydrogen at room temperature for 24h. The mixture was filtered through Celite®, rinsing with 10% aqueous ethanol. The combined filtrates were concentrated. The residue was triturated with ethyl acetate to give the title compound as a solid; MS: 261.


5    Method C

*(R)*-3-(3,5-Difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl 4-methylbenzenesulfonate



Step 1: Preparation of *(4S, 5R)*-1-[*(R)*-3-(4-methanesulfonyl-phenyl)-3-(3,5-di-fluorophenyl)-


10    propionyl]-3,4-dimethyl-5-phenyl-imidazolidin-2-one



To a mixture of copper (I) iodide (5.01g, 26.3mmol) and THF (90mL) was added *N,N,N',N'*-tetramethylethylenediamine (4.2mL, 27.6mmol) and the resulting mixture was stirred at room temperature for 10min. then cooled to -78°C. 3,5-Difluorophenylmagnesium

15    bromide (52mL, 0.5M in THF, 26.3mmol) was added and the resulting mixture stirred at -78°C for 30min. A solution of di-n-butylboron triflate (15.8mL, 1M in diethyl ether, 15.8mmol) and (*E*)-(4*S*, 5*R*)-1-(3-[4-methanesulfonylphenyl]acryloyl)-3,4-dimethyl-5-phenyl-imidazolidin-2-one (5.2 g, 13.1mmol) in THF (90mL) was added gradually and the resulting mixture was stirred whilst allowing to warm to room temperature for 18h. The reaction mixture was washed with saturated aqueous ammonium chloride then concentrated tetrasodium EDTA solution and evaporated to give a yellow solid. This was triturated with diethyl ether giving the sub-titled compound (4.04 g, 60%) as a white powder; NMR: 0.78 (d, 3H), 2.83 (s, 3H), 3.26 (s, 3H), 3.75 (dd, 1H), 4.05 (m, 2H), 4.80 (t, 1H), 5.35 (d, 1H), 7.10 (m, 3H), 7.20 (m, 2H), 7.35 (m, 3H), 7.73 (d, 2H), 7.93 (d, 2H); LC-MS: 513.

**Step 2: Preparation of (*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propanol**



To a mixture of (*4S, 5R*)-1-[(*R*)-3-(4-methanesulfonyl-phenyl)-3-(3,5-difluorophenyl)-propionyl]-3,4-dimethyl-5-phenyl-imidazolidin-2-one (57g, 111mmol) and THF (500mL) at 20°C was added lithium borohydride (2M in THF, 80mL, 160mmol) gradually. The resulting mixture was heated to reflux for 1h, cooled to 5°C and the reaction quenched by the gradual addition of 2M hydrochloric acid (200mL). The mixture was extracted with diethyl ether and the extracts dried and concentrated. The residue was triturated with ethyl acetate (200mL) and 10 the resulting mixture filtered. The filtrate was concentrated and purified by silica column chromatography (eluting with ethyl acetate) to give the sub-titled compound as an oil (25.5g); NMR ( $\text{CDCl}_3$ ): 1.65 (br s, 1H), 2.3 (m, 2H), 3.55 (m, 2H), 4.3 (t, 1H), 6.7 (m, 1H), 6.75 (m, 2H), 7.25 (d, 2H), 7.9 (d, 2H).


15 **Step 3: Preparation of title compound**

To a solution of (*R*)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propanol (6.0g, 18.4mmol) in pyridine (50mL) was added tosyl chloride (3.9g, 20mmol). The resulting mixture was stirred at 20°C for 16h. The mixture was poured onto a mixture of ice and hydrochloric acid and the resulting mixture extracted with diethyl ether. The extracts were 20 washed with 2M hydrochloric acid, water and aqueous potassium carbonate then dried ( $\text{MgSO}_4$ ) and concentrated to give the title compound (6.6g); NMR ( $\text{CDCl}_3$ ): 2.4 (m, 2H), 2.5 (s, 3H), 3.05 (s, 3H), 3.95 (t, 2H), 4.15 (d, 1H), 6.65 (m, 3H), 7.35 (m, 4H), 7.7 (d, 2H), 7.95 (d, 2H).


25 **Method D**

3-Phenyl-3-(N-methanesulphonylpiperidin-4-yl)propionaldehyde

29



**Step 1: Preparation of 4-benzoyl-1-methanesulphonylpiperidine**




Methanesulphonyl chloride was added to a stirred slurry of 4-benzoylpiperidine hydrochloride (4.51g) and triethylamine (8.35ml) in dichloromethane (100ml) at 0°C. The reaction mixture was allowed to warm to room temperature and was stirred for 16 hours. The mixture was diluted with dichloromethane (50ml) and washed with ammonium chloride solution (2x25ml) and brine (25ml), dried and evaporated to dryness to give 4-benzoyl-1-methanesulphonylpiperidine as a white solid, yield 3.98g. NMR (CDCl<sub>3</sub>): 1.93 (m, 4H), 2.81 (s, 3H), 2.98 (dt, 2H), 3.40 (m, 1H), 3.77 (m, 2H), 7.43 (t, 2H), 7.57 (t, 1H), 7.89 (d, 2H).

5      hydrochloride (4.51g) and triethylamine (8.35ml) in dichloromethane (100ml) at 0°C. The reaction mixture was allowed to warm to room temperature and was stirred for 16 hours. The mixture was diluted with dichloromethane (50ml) and washed with ammonium chloride solution (2x25ml) and brine (25ml), dried and evaporated to dryness to give 4-benzoyl-1-methanesulphonylpiperidine as a white solid, yield 3.98g. NMR (CDCl<sub>3</sub>): 1.93 (m, 4H), 2.81 (s, 3H), 2.98 (dt, 2H), 3.40 (m, 1H), 3.77 (m, 2H), 7.43 (t, 2H), 7.57 (t, 1H), 7.89 (d, 2H).

10     (s, 3H), 2.98 (dt, 2H), 3.40 (m, 1H), 3.77 (m, 2H), 7.43 (t, 2H), 7.57 (t, 1H), 7.89 (d, 2H).

**Step 2: Preparation of ethyl 3-phenyl-3-(N-methanesulphonylpiperidin-4-yl)acrylate.**



Lithium bis(trimethylsilyl)amide (16.3ml of a 1M solution in THF) was added dropwise to a solution of triethylphosphonoacetate (2.93ml) in THF at 0°C under an argon atmosphere and the mixture was stirred for 30 minutes. A slurry of 4-benzoyl-1-methanesulphonylpiperidine (3.96g) in THF (30ml) was added, the reaction mixture was allowed to warm to room temperature and stirring was continued for 24 hours. The reaction mixture was diluted with dichloromethane (80ml) and water (80ml). The organic layer was washed with water and the combined aqueous extracts were in turn extracted with dichloromethane (50ml). The combined dichloromethane extracts were washed with brine

15     dropwise to a solution of triethylphosphonoacetate (2.93ml) in THF at 0°C under an argon atmosphere and the mixture was stirred for 30 minutes. A slurry of 4-benzoyl-1-methanesulphonylpiperidine (3.96g) in THF (30ml) was added, the reaction mixture was allowed to warm to room temperature and stirring was continued for 24 hours. The reaction mixture was diluted with dichloromethane (80ml) and water (80ml). The organic layer was washed with water and the combined aqueous extracts were in turn extracted with dichloromethane (50ml). The combined dichloromethane extracts were washed with brine

20     dropwise to a solution of triethylphosphonoacetate (2.93ml) in THF at 0°C under an argon atmosphere and the mixture was stirred for 30 minutes. A slurry of 4-benzoyl-1-methanesulphonylpiperidine (3.96g) in THF (30ml) was added, the reaction mixture was allowed to warm to room temperature and stirring was continued for 24 hours. The reaction mixture was diluted with dichloromethane (80ml) and water (80ml). The organic layer was washed with water and the combined aqueous extracts were in turn extracted with dichloromethane (50ml). The combined dichloromethane extracts were washed with brine


## 30

(25ml), dried and evaporated to dryness. The residue was chromatographed on a 90g Biotage column eluted with a solvent gradient (30-5% ethyl acetate/isohexane to give a less polar fraction (1.62g) and a more polar fraction (0.53g). Both fractions (cis/trans isomers) were combined and used for the next step.

5      Less polar NMR ( $\text{CDCl}_3$ ): 1.27 (t, 3H), 1.69 (m, 2H), 1.81 (d, 2H), 2.72 (s, 3H), 2.72 (t, 2H), 3.81 (d, 2H), 3.88 (m, 1H), 4.21 (q, 2H), 5.78 (s, 1H), 7.11 (m, 2H), 7.27 (m, 3H).


More polar NMR ( $\text{CDCl}_3$ ): 1.01 (t, 3H), 1.56 (m, 2H), 1.85 (d, 2H), 2.31 (m, 1H), 2.63 (t, 2H), 2.74 (s, 3H), 3.83 (d, 2H), 3.92 (q, 3H), 5.82 (s, 1H), 7.04 (d, 2H), 7.30 (m, 3H).

10     Step 3: Preparation of ethyl 3-phenyl-3-(N-methanesulphonylpiperidin-4-yl)propionate



A solution of ethyl 3-phenyl-3-(N-methanesulphonylpiperidin-4-yl)acrylate (2.06g) in ethanol (30ml) was hydrogenated over 24 hours under a hydrogen filled balloon using 20% palladium hydroxide as catalyst. The reaction mixture was filtered through Celite® and the filtrate evaporated to dryness. The product obtained was used for the next step without further purification. MS: 340.

Step 4: 3-Phenyl-3-(N-methanesulphonylpiperidin-4-yl)propan-1-ol



20     A solution of ethyl 3-phenyl-3-(N-methanesulphonylpiperidin-4-yl)propionate (2g) in THF (10ml) was added to a suspension of lithium aluminium hydride (232mg) in THF (20ml) at 0°C under argon over 30 minutes. The reaction mixture was allowed to warm to room temperature and stirred for 2 hours. Water (10ml) was added followed by magnesium sulphate (10g). The reaction mixture was filtered and the filtrate evaporated to dryness to give the product as a white foam, yield 1.57g. NMR ( $\text{CDCl}_3$ ): 1.40 (m, 4H), 1.57 (m, 1H),

25

31

1.78 (m, 1H), 2.01 (m, 2H), 2.45 (m, 2H), 2.58 (t, 1H), 2.70 (m, 3H), 3.31 (m, 1H), 3.42 (m, 1H), 3.67 (d, 1H), 3.80 (d, 1H), 7.04 (d, 1H), 7.19 (t, 1H), 7.29 (q, 2H).


**Step 5: Preparation of the title compound**

Dess-Martin periodinane (739mg) was added to a stirred solution of 3-phenyl-3-(N-methanesulphonylpiperidin-4-yl)propan-1-ol (454mg) in dichloromethane (8ml) and stirring was continued for 2 hours. The reaction mixture was diluted with dichloromethane (100ml) and washed with 2M sodium hydroxide (2x50ml), brine (50ml) and dried. The product obtained on removal of the solvent was used in subsequent steps without purification.

10

**Method E**

(R)-3-(3,5-Difluorophenyl)-3-(4-methanesulfonylphenyl)propionaldehyde




This was prepared from (4S, 5R)-1-[(R)-3-(4-methanesulfonyl-phenyl)-3-(3,5-di-fluorophenyl)-propionyl]-3,4-dimethyl-5-phenyl-imidazolidin-2-one using a method similar to that used to prepare (S)-3-phenyl-3-(4-methanesulfonyl-phenyl)propionaldehyde from (4S, 5R)-1-[(S)-3-(4-methanesulfonyl-phenyl)-3-phenyl-propionyl]-3,4-dimethyl-5-phenyl-imidazolidin-2-one (Method A); NMR ( $\text{CDCl}_3$ ): 3.05 (s, 3H), 3.20 (d, 2H), 4.72 (t, 1H), 6.75 (m, 3H), 7.35 (d, 2H), 7.88 (d, 2H), 9.75 (s, 1H).

20


**Method F**

(R)-3-(1-Methanesulphonylpiperidin-4-yl)-3-[3,5-difluorophenyl]propionaldehyde



Step 1: 3-[N-(benzyloxycarbonylpiperidin-4-yl)]propenoic acid


32



A mixture of N-benzyloxycarbonyl-4-formylpiperidine (10g), malonic acid (4.2), pyridine (4 ml) and piperidine (0.4 ml) was heated at 100°C for 2 hours. The reaction mixture was allowed to cool and was diluted with ethyl acetate (100 ml). The solution was washed


5 with 2M HCl (2x100 ml), dried and evaporated to dryness. The residue was triturated with isohexane to give the title compound, yield 13.5g; NMR ( $\delta$ -DMSO): 1.2 (m, 2H) 1.7 (m, 2H) 2.35 (m, 1H) 2.85 (m, 2H) 4 (d, 2H) 5.05 (s, 2H) 5.75 (d, 1H) 6.75 (m, 1H) 7.35 (m, 5H) 12.25 (br, 1H).

10 Step 2: N-(benzyloxycarbonylpiperidin-4-yl)propenoic acid isopropyl ester



A solution of N-(benzyloxycarbonylpiperidin-4-yl)propenoic acid (52g) in isopropanol (500 ml) containing concentrated sulphuric acid (20 ml) was heated under reflux for 32 hours. The solvent was evaporated and the residue was dissolved in ethyl acetate (250 ml). The ethyl acetate solution was washed with water (2x250 ml) and saturated aqueous sodium bicarbonate (2x25 ml) and dried. The residue obtained on evaporation of the solvent was chromatographed on a Bond Elut cartridge eluted with a solvent gradient (isohexane-25% ethyl acetate/isohexane) to give the title compound, yield 54g.

20 Step 3: Preparation of (R)-3-(N-benzyloxycarbonylpiperidin-4-yl)-3-(3,5-difluorophenyl)propanoic acid isopropyl ester




Dioxane (100 ml) was charged to a 500 ml three necked flask and purged with argon for 10 minutes. Acetylacetonebis[ethylene]rhodium (I) (620 mg) and R-BINAP were added and the mixture was stirred for 10 minutes. 3,5-Difluorophenylboronic acid (19g) was added and the mixture was purged with argon for 10 minutes.

- 5 N-(benzyloxycarbonylpiperidin-4-yl)propenoic acid isopropyl ester (8 g) and ethanediol (20 ml) in dioxane (100 ml) were added and the mixture was purged with argon for 10 minutes. The mixture was heated at 100°C for 18 hours, allowed to cool and was passed through activated alumina (200g) washed through with ethyl acetate (3x100 ml). The combined washings were evaporated to dryness and the residue obtained was dissolved in ethyl acetate (100 ml) and washed successively with
- 10 saturated aqueous sodium bicarbonate (2x100 ml) and 2M HCl (2x100 ml), dried and evaporated to dryness. The product obtained (12g) was shown to be 40% of the required material by NMR and was used without further purification in the subsequent reactions.

**Step 4: Preparation of (*R*)-3-(piperidin-4-yl)-3-(3,5-difluorophenyl)propanoic acid isopropyl**


- 15 ester



A solution of (*R*)-3-(N-benzyloxycarbonylpiperidin-4-yl)-3-(3,5-difluorophenyl)propanoic acid isopropyl ester (12g) in ethanol (300 ml) containing 20% palladium hydroxide on charcoal (2g) was hydrogenated under a hydrogen filled balloon. The catalyst was filtered and the filtrate was evaporated to dryness to give the title compound (10g) which was used without further purification.


**Step 5: Preparation of (*R*)-3-(N-methanesulphonylpiperidin-4-yl)-3-(3,5-difluorophenyl)-propanoic acid isopropyl ester**

34



Methanesulphonyl chloride (3.7g) was added to a solution of (*R*)-3-(piperidin-4-yl)-3-(3,5-difluorophenyl)propanoic acid isopropyl ester (10g) and triethylamine (3.89g) in dichloromethane (100 ml) at 0°C. The reaction mixture was allowed to warm to room temperature and was washed with 2M HCl (2x50 ml) and saturated aqueous sodium bicarbonate (2x50 ml), dried and evaporated to dryness to give the title compound (10g) which was used without further purification.

**Step 6: Preparation of (*R*)-3-(N-methanesulphonylpiperidin-4-yl)-3-(3,5-difluorophenyl)propanol**




Lithium aluminium hydride (25 ml of a 1M solution in THF) was added dropwise over 15 minutes to a solution of (*R*)-3-(N-methanesulphonylpiperidin-4-yl)-3-(3,5-difluorophenyl)propanoic acid isopropyl ester (10g) in THF (150 ml) at -10°C. The reaction mixture was stirred at -10°C for 30 minutes, 2M NaOH (25 ml) was added, the mixture was filtered and the filtrate evaporated to dryness. The residue obtained was dissolved in ethyl acetate and washed with 2M HCl (2x100 ml) and dried. The residue obtained on removal of the solvent was chromatographed on a Bond Elut column eluting with a solvent gradient (80% ethyl acetate/isohexane-ethyl acetate) to give the title compound, yield 2.2 g; NMR ( $\delta$ -DMSO): 0.95-1.2 (m, 2H) 1.3 (m, 1H) 1.6 (m, 2H) 1.9 (m, 2H) 2.6 (m, 2H) 2.8 (s, 3H) 3.1 (m, 1H) 3.2 (m, 1H) 3.4 (m, 1H) 3.5 (m, 1H) 6.8-7.0 (m, 3H).


**Step 7: Preparation of title compound**

## 35

Dess-Martin periodinane (1g) was added to a solution of (*R*)-3-(N-methanesulphonylpiperidin-4-yl)-3-(3,5-difluorophenyl)propanol (0.8g) in dichloromethane (40 ml) and the mixture was stirred for 1.5 hours. The reaction mixture was washed with 2M NaOH (2x20 ml) and dried. The solution of the title compound in dichloromethane was used in subsequent reactions.


**Method G****(*R*)-3-(N-Methanesulphonylpiperidin-4-yl)-3-phenylpropanol**

10 Step 1: Preparation of 3-(N-methanesulphonylpiperidin-4-yl)propenoic acid acid chloride.



1-Chloro-N,N,2-trimethylpropenylamine (1.06 ml) was added dropwise over 10 minutes to a suspension of 3-(N-methanesulphonylpiperidin-4-yl)propenoic acid (1.86g, prepared from N-methanesulphonylpiperidine-4-carboxaldehyde [CAS 241134-35-0] according to step 1 of Method F) in THF (20 ml) under an atmosphere of argon and the mixture was stirred for 2 hours and used directly in step 2.


Step 2: Preparation of 1-[3-(N-methanesulphonylpiperidin-4-yl)propenyl]-(*4S, 5R*)-3,4-dimethyl-4-phenyl-imidazolidin-2-one



Lithium bis(trimethylsilyl)amide (8 ml of a 1M solution in THF) was added dropwise to a suspension of (*4R,5S*)-1,5-dimethyl-4-phenyl-2-imidazolidinone (1.52g) in THF (20 ml) under argon at -10°C. the reaction mixture was stirred at -10°C for 10 minutes, allowed to warm to 0°C and maintained at this temperature for 10 minutes then cooled again to -10°C.

5 The solution of the acid chloride prepared in Step 1 was added dropwise and the reaction mixture was allowed to warm to room temperature and washed with water (100 ml). The aqueous extract was extracted with ethyl acetate (3X50 ml) and the ethyl acetate extracts were dried and the residue passed through a 90g Biotage column eluting with a solvent gradient (50% ethyl acetate/isohexane-70% ethyl acetate/isohexane). Yield 1.89g; NMR ( $\text{CDCl}_3$ ): 0.8  
 10 (d, 3H) 1.5-1.6 (m, 3H) 1.9 (m, 2H) 2.3 (m, 1H), 2.7 (m, 2H) 2.75 (s, 3H) 2.8 (s, 3H) 3.75 (m, 2H) 3.9 (m, 1H) 5.3 (d, 1H) 6.85 (d-d, 1H) 7.1 (d, 1H) 7.2-7.35 (m, 3H) 7.45 (d, 1H).

**Step 3: Preparation of (*R*)-1-[3-phenyl-3-(methanesulphonylpiperidin-4-yl)propionyl]-  
 (*4S,5R*)-3,4-dimethyl-5-phenyl-imidazolidin-2-one**



15

A mixture of copper(I) iodide (1.78 g) and *N,N,N',N'*-tetramethylethylenediamine (1.41 ml) in THF (50 ml) was stirred under argon for 1 hour then cooled to -78°C and phenylmagnesium bromide (5.4 ml of a 1M solution in THF) was added and the mixture was stirred at -78°C for 30 minutes. A solution of 1-[3-(*N*-methanesulphonylpiperidin-4-yl)propenyl]-(*4S,5R*)-3,4-dimethyl-5-phenyl-imidazolidin-2-one (1.89g) and dibutylboron trflate (4.67 ml of a 1M solution in diethylether in THF (50 ml) was added over 10 minutes and the reaction mixture was stirred at -78°C for 1 hour then allowed to warm to room temperature. The reaction mixture was concentrated and filtered through a pad of silica (50g) washed with ethyl acetate (2x50 ml) and the ethyl acetate washings were washed with 2M HCl (2x150 ml) and dried. The residue obtained on removal of the solvent was passed through a 90g Biotage column eluting with a solvent gradient (50% ethyl acetate/isohexane-70% ethyl acetate/isohexane) to give the product as a yellow solid, yield 1.34g; NMR ( $\text{CDCl}_3$ ): 0.7 (d, 3H) 1.2 (m, 1H) 1.35 (m, 1H) 1.5 (m, 1H) 1.9 (m, 1H) 2.45 (m, 1H) 2.55 (m,

1H) 2.7 (s, 3H) 2.8 (s, 3H) 3.1 (m, 1H) 3.2 (d-d, 1H) 3.4 (m, 1H) 3.65 (m, 1H) 3.75-3.9 (m, 3H) 5.2 (d, 1H) 6.7 (d, 2H) 7.05-7.25 (m, 8H). MS: 484.

**Step 4: Preparation of the title compound**

5 A solution of (*R*)-1-[3-phenyl-3-(methanesulphonylpiperidin-4-yl)propionyl]-(4*S*,5*R*)-3,4-dimethyl-5-phenyl-imidazolidin-2-one (1.34g) in THF (14 ml) was added to a solution of lithium aluminium hydride (2.77 ml of a 1M solution in THF) in THF (10 ml) at 0°C and the mixture was allowed to warm to room temperature over 1 hour. Water (5 ml) was added cautiously, then THF (15 ml) and solid magnesium sulphate. The reaction mixture was  
10 filtered and the filtrate was passed through a 40 g Biotage column eluted with a solvent gradient (50% ethyl acetate/isohexane-70% ethyl acetate/isohexane) to give the title compound as a white solid, yield 338 mg; NMR (CDCl<sub>3</sub>): 1.15-1.25 (m, 2H) 1.3-1.5 (m, 2H) 1.6 (m, 1H) 1.75 (m, 1H) 1.95-2.10 (m, 2H) 2.5 (m, 2H) 2.6 (m, 1H) 2.7 (s, 3H) 3.3-3.4 (m, 2H) 3.45 (m, 1H) 3.7 (m, 1H) 3.85 (m, 1H) 7.05 (m, 2H) 7.15-7.35 (m, 3H).

15

Example 2

The ability of compounds to inhibit the binding of MIP-1 $\alpha$  was assessed by an *in vitro* radioligand binding assay. Membranes were prepared from Chinese hamster ovary cells which expressed the recombinant human CCR5 receptor. These membranes were incubated  
20 with 0.1nM iodinated MIP-1 $\alpha$ , scintillation proximity beads and various concentrations of the compounds of the invention in 96-well plates. The amount of iodinated MIP-1 $\alpha$  bound to the receptor was determined by scintillation counting. Competition curves were obtained for compounds and the concentration of compound which displaced 50% of bound iodinated MIP-1 $\alpha$  was calculated (IC<sub>50</sub>). Certain compounds of formula (I) have an IC<sub>50</sub> of less than  
25 50 $\mu$ M.

Results from this test for certain compounds of the invention are presented in Table IV. In Table IV the results are presented as Pic50 values. A Pic50 value is the negative log (to base 10) of the IC<sub>50</sub> result, so an IC<sub>50</sub> of 1 $\mu$ M (that is 1  $\times$  10<sup>-6</sup>M) gives a Pic50 of 6. If a compound was tested more than once then the data below is an average of the probative tests  
30 results.

TABLE IV

Table Number	Compound number	Pic50
--------------	-----------------	-------

DDMV 07-07-10


38

III	I	8.5
-----	---	-----

101145-1 SB

Scheme 1

To prepare compounds of the invention, for example wherein R<sup>1</sup> is aryl or C-linked piperidine.



5.



- i      Wittig reaction (eg LHDMS, triethylphosphonoacetate)
- ii     Catalytic hydrogenation (eg H<sub>2</sub>, 10% Pd/C)
- iii    Reduction (eg LAH)
- iv    Oxidation (eg Dess-Martin oxidation)

10

- v     reductive amination with (eg using sodium triacetoxyborohydride)

Scheme 2

To prepare compounds of the invention, for example wherein R<sup>1</sup> is aryl or C-linked piperidine.



5

i Base hydrolysis (eg LiOH, MeOH/H<sub>2</sub>O)ii MeMgCl, R<sup>3</sup>MgBr, Et<sub>2</sub>O

iii reductive amination in presence of titanium tetraisopropoxide (eg using sodium triacetoxyborohydride)


10

 1  
0  
9  
8  
7  
6  
5  
4  
3  
2  
1

41

Scheme 3


To prepare compounds of the invention, for example wherein R<sup>1</sup> is aryl, heteroaryl, heterocycl or NR<sup>13</sup>C(O)R<sup>14</sup>.



5 in which L is an activated group, such as halogen, mesylate, tosylate or triflate.

Scheme 4


To prepare compounds of the invention, for example wherein R<sup>1</sup> is aryl, heteroaryl or heterocycl.



in which L<sup>1</sup> is a halogen, an activated ester or a complex formed with a carbodiimide.

Scheme 5

To prepare compounds of the invention, for example wherein R<sup>1</sup> is NR<sup>13</sup>C(O)R<sup>14</sup>.




i reductive amination (if R<sup>3</sup> is H can use sodium triacetoxyborohydride; if R<sup>3</sup> is alkyl  
 5 can use titanium tetra-isopropoxide and sodium triacetoxyborohydride)  
 ii Deprotection (eg TFA)  
 iii amide bond formation (eg acid chloride, active ester or carbodiimide mediated)

101145-1 SE

43

Scheme 6

To prepare compounds of the invention, for example wherein R<sup>1</sup> is piperazine.



5    i    Conversion of an OH to a leaving group (eg tosyl chloride (L<sup>2</sup> is Tosylate) or mesyl chloride (L<sup>2</sup> is Mesylate))



(eg in presence of triethylamine)

ii    displacement reaction with

iii    Mesyl chloride, DCM 0°C

iv    Displacement reaction with mono-protected piperazine (P is a protecting group)

10    v    Displacement reaction with R substituted piperazine


vi    Deprotection (TFA for Boc, hydrogenation for Cbz)

vii    Depending on R, acylation, sulphonylation, alkylation, reductive amination

44

Scheme 7

To prepare compounds of the invention, for example wherein R<sup>1</sup> is aryl or piperidine.



5    i    activation of acid group and coupling with chiral auxiliary (eg SOCl<sub>2</sub>,

ii    1,4-addition of organocuprate (eg R<sup>2</sup>MgBr, Cu(I)I, TMEDA, di-butylboron triflate)

iii    reduction (eg lithium aluminium hydride)


iv    Dibal

v    Oxidation (eg Dess-Martin reagent)

10   vi    reductive amination (eg with sodium triacetoxyborohydride)

CLAIMS

## 1. A compound of formula (I):



5 wherein:

A is absent or is (CH<sub>2</sub>)<sub>2</sub>;

R<sup>1</sup> is C(O)NR<sup>10</sup>R<sup>11</sup>, C(O)<sub>2</sub>R<sup>12</sup>, NR<sup>13</sup>C(O)R<sup>14</sup>, NR<sup>15</sup>C(O)NR<sup>16</sup>R<sup>17</sup>, NR<sup>18</sup>C(O)<sub>2</sub>R<sup>19</sup>, heterocyclyl (for example piperidine, piperazine, pyrrolidine or azetidine), aryl or heteroaryl;

10 R<sup>10</sup>, R<sup>13</sup>, R<sup>15</sup>, R<sup>16</sup> and R<sup>18</sup> are hydrogen or C<sub>1-6</sub> alkyl;  
 R<sup>11</sup>, R<sup>12</sup>, R<sup>14</sup>, R<sup>17</sup> and R<sup>19</sup> are C<sub>1-8</sub> alkyl (optionally substituted by halo, hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, C<sub>3-6</sub> cycloalkyl (optionally substituted by halo), C<sub>3-6</sub> cycloalkenyl, S(C<sub>1-4</sub> alkyl), S(O)(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), heteroaryl, aryl, heteroaryloxy or aryloxy), aryl, heteroaryl, C<sub>3-7</sub> cycloalkyl (optionally substituted by halo or C<sub>1-4</sub> alkyl), C<sub>4-7</sub> cycloalkyl fused to a phenyl ring, C<sub>5-7</sub> cycloalkenyl, or, heterocyclyl (itself optionally substituted by oxo, C(O)(C<sub>1-6</sub> alkyl), S(O)<sub>k</sub>(C<sub>1-6</sub> alkyl), halo or C<sub>1-4</sub> alkyl); or R<sup>11</sup>, R<sup>12</sup>, R<sup>14</sup> and R<sup>17</sup> can also be hydrogen; or R<sup>10</sup> and R<sup>11</sup>, and/or R<sup>16</sup> and R<sup>17</sup> may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C<sub>1-6</sub> alkyl, S(O)<sub>l</sub>(C<sub>1-6</sub> alkyl) or C(O)(C<sub>1-6</sub> alkyl);

15 R<sup>2</sup> is phenyl, heteroaryl or C<sub>3-7</sub> cycloalkyl;

R<sup>3</sup> is H or C<sub>1-4</sub> alkyl;R<sup>4</sup> is heterocyclyl;

n is 1, 2 or 3;

20 aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, cyano, nitro, hydroxy, OC(O)NR<sup>20</sup>R<sup>21</sup>, NR<sup>22</sup>R<sup>23</sup>, NR<sup>24</sup>C(O)R<sup>25</sup>, NR<sup>26</sup>C(O)NR<sup>27</sup>R<sup>28</sup>, S(O)<sub>2</sub>NR<sup>29</sup>R<sup>30</sup>, NR<sup>31</sup>S(O)<sub>2</sub>R<sup>32</sup>, C(O)NR<sup>33</sup>R<sup>34</sup>, CO<sub>2</sub>R<sup>36</sup>, NR<sup>37</sup>CO<sub>2</sub>R<sup>38</sup>, S(O)<sub>q</sub>R<sup>39</sup>, OS(O)<sub>2</sub>R<sup>49</sup>, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>3-10</sub> cycloalkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkoxy(C<sub>1-6</sub>)alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, phenyl, phenyl(C<sub>1-4</sub>)alkyl, phenoxy, phenylthio, phenylS(O), phenylS(O)<sub>2</sub>, phenyl(C<sub>1-4</sub>)alkoxy, heteroaryl,

heteroaryl(C<sub>1-4</sub>)alkyl, heteroaryloxy or heteroaryl(C<sub>1-4</sub>)alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(C<sub>1-4</sub> alkyl), S(O)(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>NH<sub>2</sub>, S(O)<sub>2</sub>NH(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>N(C<sub>1-4</sub> alkyl)<sub>2</sub>, cyano, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C(O)NH<sub>2</sub>, C(O)NH(C<sub>1-4</sub> alkyl), C(O)N(C<sub>1-4</sub> alkyl)<sub>2</sub>, CO<sub>2</sub>H, CO<sub>2</sub>(C<sub>1-4</sub> alkyl), NHC(O)(C<sub>1-4</sub> alkyl), NHS(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), CF<sub>3</sub> or OCF<sub>3</sub>;

unless otherwise stated heterocyclyl is optionally substituted by C<sub>1-6</sub> alkyl [optionally substituted by phenyl {which itself optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, cyano, nitro, CF<sub>3</sub>, (C<sub>1-4</sub> alkyl)C(O)NH, S(O)<sub>2</sub>NH<sub>2</sub>, C<sub>1-4</sub> alkylthio, S(O)(C<sub>1-4</sub> alkyl) or S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl)} or heteroaryl {which itself optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, cyano, nitro, CF<sub>3</sub>, (C<sub>1-4</sub> alkyl)C(O)NH, S(O)<sub>2</sub>NH<sub>2</sub>, C<sub>1-4</sub> alkylthio, S(O)(C<sub>1-4</sub> alkyl) or S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl)}], phenyl {optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, cyano, nitro, CF<sub>3</sub>, OCF<sub>3</sub>, (C<sub>1-4</sub> alkyl)C(O)NH, S(O)<sub>2</sub>NH<sub>2</sub>, C<sub>1-4</sub> alkylthio, S(O)(C<sub>1-4</sub> alkyl) or S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl)}, heteroaryl {optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, cyano, nitro, CF<sub>3</sub>, (C<sub>1-4</sub> alkyl)C(O)NH, S(O)<sub>2</sub>NH<sub>2</sub>, C<sub>1-4</sub> alkylthio, S(O)(C<sub>1-4</sub> alkyl) or S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl)}, S(O)<sub>2</sub>NR<sup>40</sup>R<sup>41</sup>, C(O)R<sup>42</sup>, C(O)<sub>2</sub>(C<sub>1-6</sub> alkyl) (such as tert-butoxycarbonyl), C(O)<sub>2</sub>(phenyl(C<sub>1-2</sub> alkyl)) (such as benzyloxycarbonyl), C(O)NHR<sup>43</sup>, S(O)<sub>2</sub>R<sup>44</sup>, NHS(O)<sub>2</sub>NHR<sup>45</sup>, NHC(O)R<sup>46</sup>, NHC(O)NHR<sup>47</sup> or NHS(O)<sub>2</sub>R<sup>48</sup>, provided none of these last four substituents is linked to a ring nitrogen;

k, l and q are, independently, 0, 1 or 2;

R<sup>20</sup>, R<sup>22</sup>, R<sup>24</sup>, R<sup>26</sup>, R<sup>27</sup>, R<sup>29</sup>, R<sup>31</sup>, R<sup>33</sup>, R<sup>37</sup>, R<sup>40</sup> and R<sup>51</sup> are, independently, hydrogen or C<sub>1-6</sub> alkyl;

R<sup>21</sup>, R<sup>23</sup>, R<sup>25</sup>, R<sup>28</sup>, R<sup>30</sup>, R<sup>32</sup>, R<sup>34</sup>, R<sup>36</sup>, R<sup>38</sup>, R<sup>39</sup>, R<sup>41</sup>, R<sup>42</sup>, R<sup>43</sup>, R<sup>44</sup>, R<sup>45</sup>, R<sup>46</sup>, R<sup>47</sup>, R<sup>48</sup>, R<sup>49</sup>, R<sup>50</sup> and R<sup>52</sup> are, independently, C<sub>1-6</sub> alkyl (optionally substituted by halo, hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, C<sub>3-6</sub> cycloalkyl, C<sub>5-6</sub> cycloalkenyl, S(C<sub>1-4</sub> alkyl), S(O)(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), heteroaryl, phenyl, heteroaryloxy or phenoxy), C<sub>3-7</sub> cycloalkyl, phenyl or heteroaryl; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(C<sub>1-4</sub> alkyl), S(O)(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>NH<sub>2</sub>, S(O)<sub>2</sub>NH(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>N(C<sub>1-4</sub> alkyl)<sub>2</sub>, cyano, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C(O)NH<sub>2</sub>, C(O)NH(C<sub>1-4</sub> alkyl), C(O)N(C<sub>1-4</sub> alkyl)<sub>2</sub>, CO<sub>2</sub>H, CO<sub>2</sub>(C<sub>1-4</sub> alkyl), NHC(O)(C<sub>1-4</sub> alkyl), NHS(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), C(O)(C<sub>1-4</sub> alkyl), CF<sub>3</sub> or OCF<sub>3</sub>;

47

$R^{21}$ ,  $R^{23}$ ,  $R^{25}$ ,  $R^{28}$ ,  $R^{30}$ ,  $R^{34}$ ,  $R^{35}$ ,  $R^{36}$ ,  $R^{41}$ ,  $R^{42}$ ,  $R^{43}$ ,  $R^{45}$ ,  $R^{46}$ ,  $R^{47}$  and  $R^{52}$  may additionally be hydrogen; or a pharmaceutically acceptable salt thereof or a solvate thereof.

5    2. Processes for preparing a compound as claimed in claim 1.

3. A pharmaceutical composition which comprises a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof or solvate thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier.

10    4. A compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof or solvate thereof, for use as a medicament.

15    5. A compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof or solvate thereof, in the manufacture of a medicament for use in therapy.


6. A method of treating a CCR5 mediated disease state comprising administering to a patient in need of such treatment an effective amount of a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof or solvate thereof.

20

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
3310  
3311  
3312  
3313  
3314  
3315  
3316  
3317  
3318  
3319  
3320  
3321  
3322  
3323  
3324  
3325  
3326  
3327  
3328  
3329  
3330  
3331  
3332  
3333  
3334  
3335  
3336  
3337  
3338  
3339  
3340  
3341  
3342  
3343  
3344  
3345  
3346  
3347  
3348  
3349  
3350  
3351  
3352  
3353  
3354  
3355  
3356  
3357  
3358  
3359  
33510  
33511  
33512  
33513  
33514  
33515  
33516  
33517  
33518  
33519  
33520  
33521  
33522  
33523  
33524  
33525  
33526  
33527  
33528  
33529  
33530  
33531  
33532  
33533  
33534  
33535  
33536  
33537  
33538  
33539  
33540  
33541  
33542  
33543  
33544  
33545  
33546  
33547  
33548  
33549  
33550  
33551  
33552  
33553  
33554  
33555  
33556  
33557  
33558  
33559  
33560  
33561  
33562  
33563  
33564  
33565  
33566  
33567  
33568  
33569  
33570  
33571  
33572  
33573  
33574  
33575  
33576  
33577  
33578  
33579  
33580  
33581  
33582  
33583  
33584  
33585  
33586  
33587  
33588  
33589  
33590  
33591  
33592  
33593  
33594  
33595  
33596  
33597  
33598  
33599  
335100  
335101  
335102  
335103  
335104  
335105  
335106  
335107  
335108  
335109  
335110  
335111  
335112  
335113  
335114  
335115  
335116  
335117  
335118  
335119  
335120  
335121  
335122  
335123  
335124  
335125  
335126  
335127  
335128  
335129  
335130  
335131  
335132  
335133  
335134  
335135  
335136  
335137  
335138  
335139  
335140  
335141  
335142  
335143  
335144  
335145  
335146  
335147  
335148  
335149  
335150  
335151  
335152  
335153  
335154  
335155  
335156  
335157  
335158  
335159  
335160  
335161  
335162  
335163  
335164  
335165  
335166  
335167  
335168  
335169  
335170  
335171  
335172  
335173  
335174  
335175  
335176  
335177  
335178  
335179  
335180  
335181  
335182  
335183  
335184  
335185  
335186  
335187  
335188  
335189  
335190  
335191  
335192  
335193  
335194  
335195  
335196  
335197  
335198  
335199  
335200  
335201  
335202  
335203  
335204  
335205  
335206  
335207  
335208  
335209  
335210  
335211  
335212  
335213  
335214  
335215  
335216  
335217  
335218  
335219  
335220  
335221  
335222  
335223  
335224  
335225  
335226  
335227  
335228  
335229  
335230  
335231  
335232  
335233  
335234  
335235  
335236  
335237  
335238  
335239  
335240  
335241  
335242  
335243  
335244  
335245  
335246  
335247  
335248  
335249  
335250  
335251  
335252  
335253  
335254  
335255  
335256  
335257  
335258  
335259  
335260  
335261  
335262  
335263  
335264  
335265  
335266  
335267  
335268  
335269  
335270  
335271  
335272  
335273  
335274  
335275  
335276  
335277  
335278  
335279  
335280  
335281  
335282  
335283  
335284  
335285  
335286  
335287  
335288  
335289  
335290  
335291  
335292  
335293  
335294  
335295  
335296  
335297  
335298  
335299  
335300  
335301  
335302  
335303  
335304  
335305  
335306  
335307  
335308  
335309  
335310  
335311  
335312  
335313  
335314  
335315  
335316  
335317  
335318  
335319  
335320  
335321  
335322  
335323  
335324  
335325  
335326  
335327  
335328  
335329  
335330  
335331  
335332  
335333  
335334  
335335  
335336  
335337  
335338  
335339  
335340  
335341  
335342  
335343  
335344  
335345  
335346  
335347  
335348  
335349  
335350  
335351  
335352  
335353  
335354  
335355  
335356  
335357  
335358  
335359  
335360  
335361  
335362  
335363  
335364  
335365  
335366  
335367  
335368  
335369  
335370  
335371  
335372  
335373  
335374  
335375  
335376  
335377  
335378  
335379  
335380  
335381  
335382  
335383  
335384  
335385  
335386  
335387  
335388  
335389  
335390  
335391  
335392  
335393  
335394  
335395  
335396  
335397  
335398  
335399  
335400  
335401  
335402  
335403  
335404  
335405  
335406  
335407  
335408  
335409  
335410  
335411  
335412  
335413  
335414  
335415  
335416  
335417  
335418  
335419  
335420  
335421  
335422  
335423  
335424  
335425  
335426  
335427  
335428  
335429  
335430  
335431  
335432  
335433  
335434  
335435  
335436  
335437  
335438  
335439  
335440  
335441  
335442  
335443  
335444  
335445  
335446  
335447  
335448  
335449  
335450  
335451  
335452  
335453  
335454  
335455  
335456  
335457  
335458  
335459  
335460  
335461  
335462  
335463  
335464  
335465  
335466  
335467  
335468  
335469  
335470  
335471  
335472  
335473  
335474  
335475  
335476  
335477  
335478  
335479  
335480  
335481  
335482  
335483  
335484  
335485  
335486  
335487  
335488  
335489  
335490  
335491  
335492  
335493  
335494  
335495  
335496  
335497  
335498  
335499  
335500  
335501  
335502  
335503  
335504  
335505  
335506  
335507  
335508  
335509  
335510  
335511  
335512  
335513  
335514  
335515  
335516  
335517  
335518  
335519  
335520  
335521  
335522  
335523  
335524  
335525  
335526  
335527  
335528  
335529  
335530  
335531  
335532  
335533  
335534  
335535  
335536  
335537  
335538  
335539  
335540  
335541  
335542  
335543  
335544  
335545  
335546  
335547  
335548  
335549  
335550  
335551  
335552  
335553  
335554  
335555  
335556  
335557  
335558  
335559  
335560  
335561  
335562  
335563  
335564  
335565  
335566  
335567  
335568  
335569  
335570  
335571  
335572  
335573  
335574  
335575  
335576  
335577  
335578  
335579  
335580  
335581  
335582  
335583  
335584  
335585  
335586  
335587  
335588  
335589  
335590  
335591  
335592  
335593  
335594  
335595  
335596  
335597  
335598  
335599  
3355100  
3355101  
3355102  
3355103  
3355104  
3355105  
3355106  
3355107  
3355108  
3355109  
3355110  
3355111  
3355112  
3355113  
3355114  
3355115  
3355116  
3355117  
3355118  
3355119  
3355120  
3355121  
3355122  
3355123  
3355124  
3355125  
3355126  
3355127  
3355128  
3355129  
3355130  
3355131  
3355132  
3355133  
3355134  
3355135  
3355136  
3355137  
3355138  
3355139  
3355140  
3355141  
3355142  
3355143  
3355144  
3355145  
3355146  
3355147  
3355148  
3355149  
3355150  
3355151  
3355152  
3355153  
3355154  
3355155  
3355156  
3355157  
3355158  
3355159  
3355160  
3355161  
3355162  
3355163  
3355164  
3355165  
3355166  
3355167  
3355168  
3355169  
3355170  
3355171  
3355172  
3355173  
3355174  
3355175  
3355176  
3355177  
3355178  
3355179  
3355180  
3355181  
3355182  
3355183  
3355184  
3355185  
3355186  
3355187  
3355188  
3355189  
3355190  
3355191  
3355192  
3355193  
3355194  
3355195  
3355196  
3355197  
3355198  
3355199  
3355200  
3355201  
3355202  
3355203  
3355204  
3355205  
3355206  
3355207  
3355208  
3355209  
3355210  
3355211  
3355212  
3355213  
3355214  
3355215  
3355216  
3355217  
3355218  
3355219  
3355220  
3355221  
3355222  
3355223  
3355224  
3355225  
3355226  
3355227  
3355228  
3355229  
3355230  
3355231  
3355232  
3355233  
3355234  
3355235  
3355236  
3355237  
3355238  
3355239  
3355240  
3355241  
3355242  
3355243  
3355244  
3355245  
3355246  
3355247  
3355248  
3355249  
3355250  
3355251  
3355252  
3355253  
3355254  
3355255  
3355256  
3355257  
3355258  
3355259  
3355260  
3355261  
3355262  
3355263  
3355264  
3355265  
3355266  
3355267  
3355268  
3355269  
3355270  
3355271  
3355272  
3355273  
3355274  
3355275  
3355276  
3355277  
3355278  
3355279  
3355280  
3355281  
3355282  
3355283  
3355284  
3355285  
3355286  
3355287  
3355288  
3355289  
3355290  
3355291  
3355292  
3355293  
3355294  
3355295  
3355296  
3355297  
3355298  
3355299  
3355300  
3355301  
3355302  
3355303  
3355304  
3355305  
3355306  
3355307  
3355308  
3355309  
3355310  
3355311  
3355312  
3355313  
3355314  
3355315  
3355316  
3355317  
3355318  
3355319  
3355320  
3355321  
3355322  
3355323  
3355324  
3355325  
3355326  
3355327  
3355328  
3355329  
3355330  
3355331  
3355332  
3355333  
3355334  
3355335  
3355336  
3355337  
3355338  
3355339  
3355340  
3355341  
3355342  
3355343  
3355344  
3355345  
3355346  
3355347  
3355348  
3355349  
3355350  
3355351  
3355352  
3355353  
3355354  
3355355  
3355356  
3355357  
3355358  
3355359  
3355360  
3355361  
3355362  
3355363  
3355364  
3355365  
3355366  
3355367  
3355368  
3355369  
3355370  
3355371  
3355372  
3355373  
3355374  
3355375  
3355376  
3355377  
3355378  
3355379  
3355380  
3355381  
3355382  
3355383  
3355384  
3355385  
3355386  
3355387  
3355388  
3355389  
3355390  
3355391  
3355392  
3355393  
3355394  
3355395  
3355396  
3355397  
3355398  
3355399  
3355400  
3355401  
3355402  
3355403  
3355404  
3355405  
3355406  
3355407  
3355408  
3355409  
3355410  
3355411  
3355412  
3355413  
3355414  
3355415  
3355416  
3355417  
3355418  
3355419  
3355420  
3355421  
3355422  
3355423  
3355424  
3355425  
3355426  
3355427  
3355428  
3355429  
3355430  
3355431  
3355432  
3355433  
3355434  
3355435  
3355436  
3355437  
3355438  
3355439  
3355440  
3355441  
3355442  
3355443  
3355444  
3355445  
3355446  
3355447  
3355448  
3355449  
3355450  
3355451  
3355452  
3355453  
3355454  
3355455  
3355456  
3355457  
3355458  
3355459  
3355460  
3355461  
3355462  
3355463  
3355464  
3355465  
3355466  
3355467  
3355468  
3355469  
3355470  
3355471  
3355472  
3355473  
3355474  
3355475  
3355476  
3355477  
3355478  
3355479  
3355480  
3355481  
3355482  
3355483  
3355484  
3355485  
3355486  
3355487  
3355488  
3355489  
3355490  
3355491  
3355492  
3355493  
3355494  
3355495  
3355496  
3355497  
3355498  
3355499  
3355500  
3355501  
3355502  
3355503  
3355504  
3355505  
3355506  
3355507  
3355508  
3355509  
3355510  
3355511  
3355512  
3355513  
3355514  
3355515  
3355516  
3355517  
3355518  
3355519  
3355520  
3355521  
3355522  
3355523  
3355524  
3355525  
3355526  
3355527  
3355528  
3355529  
3355530  
3355531  
3355532  
3355533  
3355534  
3355535  
3355536  
3355537  
3355538  
3355539  
3355540  
3355541  
3355542  
3355543  
3355544  
3355545  
3355546  
3355547  
3355548  
3355549  
3355550  
3355551  
3355552  
3355553  
3355554  
3355555  
3355556  
3355557  
3355558  
3355559  
3355560  
3355561  
3355562  
3355563  
3355564  
3355565  
3355566  
3355567  
3355568  
3355569  
3355570  
3355571  
3355572  
3355573  
3355574  
33555

**ABSTRACT**  
**CHEMICAL COMPOUNDS**

**Compounds of formula (I):**



wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, A and n are as defined; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).

101143-1 SE

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**